**Title:** Association of upper respiratory *Streptococcus pneumoniae* colonization with SARS-CoV-2 infection among adults

**Authors:** Anna M. Parker<sup>1</sup>, Nicole Jackson<sup>1</sup>, Shevya Awasthi<sup>1</sup>, Hanna Kim<sup>1</sup>, Tess Alwan<sup>1</sup>, Anne L. Wyllie<sup>2</sup>, Alisha B. Baldwin<sup>3</sup>, Nicole B. Brennick<sup>3</sup>, Erica A. Moehle<sup>3</sup>, Petros Giannikopoulos<sup>3</sup>, Katherine Kogut<sup>4</sup>, Nina Holland<sup>4</sup>, Ana Mora-Wyrobek<sup>4</sup>, Brenda Eskenazi<sup>4</sup>, Lee W. Riley<sup>1</sup>, Joseph A. Lewnard<sup>1,5,6,\*</sup>

# Affiliations:

- 1. Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
- 2. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut 06510, United States
- 3. Innovative Genomics Institute, University of California, Berkeley, Berkeley, California 94720, United States
- 4. Center for Environmental Research & Community Health, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
- 5. Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
- 6. Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California 94720, United States
- \* Address for correspondence: Joseph Lewnard 2121 Berkeley Way Berkeley, California 94720 United States jLewnard@berkeley.edu (847) 507-6115

Running head: Pneumococcal/SARS-CoV-2 interactions

# Key points:

- In an adult ambulatory and community sample, SARS-CoV-2 infection was more prevalent among pneumococcal carriers than non-carriers.
- Associations between pneumococcal carriage and SARS-CoV-2 infection were strongest among adults reporting acute symptoms and receiving SARS-CoV-2 testing in a clinical setting.

## Word count

Key points: 39 Abstract: 250 Main text: 2,993

## ABSTRACT

**Background:** *Streptococcus pneumoniae* interacts with numerous viral respiratory pathogens in the upper airway. It is unclear whether similar interactions occur with SARS-CoV-2.

**Methods:** We collected saliva specimens from working-age adults receiving SARS-CoV-2 molecular testing at outpatient clinics and via mobile community-outreach testing between July and November 2020 in Monterey County, California. Following bacterial culture enrichment, we tested for pneumococci by quantitative polymerase chain reaction (qPCR) targeting the *lytA* and *piaB* genes, and measured associations with SARS-CoV-2 infection via conditional logistic regression.

**Results:** Analyses included 1,278 participants, with 564 enrolled in clinics and 714 enrolled through outreachbased testing. Prevalence of pneumococcal carriage was 9.2% (117/1,278) among all participants (11.2% [63/564] clinic-based testing; 7.6% [54/714] outreach testing). Prevalence of SARS-CoV-2 infection was 27.4% (32/117) among pneumococcal carriers and 9.6% (112/1,161) among non-carriers (adjusted odds ratio [aOR]: 2.73; 95% confidence interval: 1.58-4.69). Associations between SARS-CoV-2 infection and pneumococcal carriage were enhanced in the clinic-based sample (aOR=4.01 [2.08-7.75]) and among symptomatic participants (aOR=3.38 [1.35-8.40]), when compared to findings within the outreach-based sample and among asymptomatic participants. Adjusted odds of SARS-CoV-2 co-infection increased 1.24 (1.00-1.55)-fold for each 1-unit decrease in *piaB* qPCR C<sub>T</sub> value among pneumococcal carriers. Last, pneumococcal carriage modified the association of SARS-CoV-2 infection with recent exposure to a suspected COVID-19 case (aOR=7.64 [1.91-30.7] and 3.29 [1.94-5.59]) among pneumococcal carriers and non-carriers, respectively).

**Conclusions:** Associations of pneumococcal carriage detection and density with SARS-CoV-2 suggest a synergistic relationship in the upper airway. Longitudinal studies are needed to determine interaction mechanisms between pneumococci and SARS-CoV-2.

Key words: Pneumococcus; SARS-CoV-2; viral-bacterial interaction; carriage

#### INTRODUCTION

Interactions involving *Streptococcus pneumoniae* and respiratory viruses feature in the natural history of multiple clinical conditions. Pneumococcal pneumonia and invasive pneumococcal disease (IPD) incidence rates align with seasonal influenza and respiratory syncytial virus (RSV) transmission,<sup>1,2</sup> and severe pneumococcal infections are prominent sequelae of viral respiratory disease.<sup>3</sup> Interactions also arise earlier in the clinical course, including when symptoms are absent. Epidemiologic studies of influenza virus, RSV, human rhinoviruses, and endemic human coronaviruses have revealed frequent co-detection of pneumococci in the upper airway, often in association with increased density of bacterial shedding.<sup>4-11</sup> Likewise, experimental challenge models in animals<sup>12</sup> and humans<sup>13,14</sup> have revealed effects of pneumococcal carriage on influenza virus acquisition and immune response, while epidemiologic studies have identified increased risk of viral acquisition and acute respiratory infection associated with the presence and density of pneumococcal carriage.<sup>15</sup>

It is unclear whether similar interactions occur between pneumococci and SARS-CoV-2. Contrary to experience with influenza, early investigations identified low risk of severe secondary pneumococcal infections among COVID-19 patients,<sup>16</sup> although such studies may have been limited by choice of pneumococcal detection methods and prevalent antibiotic prescribing for COVID-19 patients during the early pandemic.<sup>17,18</sup> Among healthcare workers in the United Kingdom, SARS-CoV-2 infection was associated with three-fold higher likelihood of molecular detection of pneumococcal carriage in saliva; moreover, pneumococcal carriers experienced diminished IgA and CD4<sup>+</sup> T-cell responses to SARS-CoV-2 after recovery.<sup>19</sup> SARS-CoV-2 acquisition concurrent with or shortly following IPD was associated with enhanced mortality in a UK surveillance study.<sup>20</sup> Last, among adults aged ≥65 years in the United States, receipt of 13-valent pneumococcal conjugate vaccine (PCV13) was associated with reduced risk of COVID-19 diagnosis, hospital admission, and mortality.<sup>21</sup> These findings reflect moderate PCV effectiveness against virus-associated lower respiratory tract infection (LRTI) and pneumonia among children and adults in prior studies.<sup>22-25</sup>

To understand potential interactions between pneumococci and SARS-CoV-2, we evaluated pneumococcal carriage within a study of SARS-CoV-2 infection among adult farmworkers in Monterey County, California undertaken between July and November, 2020.<sup>26</sup> We aimed to assess whether pneumococcal carriage was associated with SARS-CoV-2 infection, and to evaluate how this association varied according to pneumococcal carriage density and clinical symptoms.

## **METHODS**

# Study setting and recruitment

Primary study methods and findings have been reported previously.<sup>26-28</sup> Briefly, we enrolled adults currently or previously employed in agricultural work through no-cost, point-of-care molecular SARS-CoV-2 testing at ambulatory outpatient clinics and mobile community outreach venues operated by Clínica de Salud del Valle de Salinas (CSVS) throughout Monterey County, California, from 16 July to 30 November, 2020. CSVS is a Federally-Qualified Health Center serving >50,000 patients, primarily focused on healthcare for local agricultural workers and their families. Most farmworkers in the region are Latino and live below the federal poverty line.<sup>29</sup> SARS-CoV-2 test positivity among these farmworkers was higher than among other adults in Monterey County throughout the study period.<sup>26</sup>

Healthcare providers at CSVS recommended SARS-CoV-2 testing for all patients, regardless of symptoms, during the study period. Outreach testing was also conducted at community sites throughout the Salinas Valley, including low-income and agricultural employer-provided housing facilities, agricultural fields, and health fairs. Individuals eligible for the primary study were nonpregnant adult farmworkers aged ≥18 years who received SARS-CoV-2 testing at CSVS, who had not previously participated in the study, and who spoke sufficient Spanish or English to provide consent and complete study procedures. For this ancillary study of pneumococcal carriage, we expanded recruitment to include any other adults (not exclusively farmworkers) who received SARS-CoV-2 testing at CSVS, who spoke Spanish or English and agreed to provide a saliva sample.

Participants provided  $\geq 3_mL$  of saliva passively pooling in the front of the mouth into  $\geq 20_mL$  screw-top collection tubes. Participants responded to a standardized survey covering demographics, clinical symptoms, and recent exposures by telephone interview within 48 hours of their testing appointment, before SARS-CoV-2 testing results were notified. Participants who were not farmworkers and enrolled in the pneumococcal substudy only answered a shortened survey.

## **Outcome definitions**

We determined pneumococcal carriage via quantitative polymerase chain reaction (qPCR) assays targeting the *lytA* and *piaB* genes, using bacterial DNA extracted after a culture-enrichment step according to previouslyvalidated protocols<sup>30</sup> (**Text S1**). Samples with *lytA* cycle threshold ( $C_T$ ) values <40 were tested for the *piaB* gene and were considered to contain pneumococci if both *lytA* and *piaB*  $C_T$  values were <40 (**Table S1**). We additionally report results applying a more stringent threshold of *lytA* and *piaB*  $C_T$  values <35. Clinical testing for SARS-CoV-2 from oropharyngeal specimens was conducted via the qualitative Aptima SARS-CoV-2 (Hologic; Marlborough, Massachusetts, US) transcription-mediated amplification (TMA) assay. We considered individuals with positive results for SARS-CoV-2 by this clinical test to be infected. For secondary analyses addressing SARS-CoV-2 viral abundance, we also used  $C_T$  values from qPCR-based detection of the SARS-CoV-2 nucleocapsid (N) and structural envelope protein (E) genes in saliva specimens (**Text S1**).

## Statistical analysis

We first compared prevalence of SARS-CoV-2 infection among pneumococcal carriers and non-carriers. We fit conditional logistic regression models defining SARS-CoV-2 infection as the outcome and pneumococcal carriage as the primary exposure of interest, with strata for participants' recruitment setting (clinic-based testing or mobile outreach testing) to address differences in the populations reached. We computed adjusted odds ratios (aORs) adjusting for risk factors including participants' age, sex, body mass index (BMI), community of residence, current or former smoking, residence type, educational background, household annual income,

language spoken, exposure to children aged <5 years, and potential COVID-19 related exposures and risk behaviors in the prior two weeks. These included contact with a confirmed or suspected COVID-19 case, mask-wearing in indoor public settings, attendance at indoor gatherings with individuals from outside participants' households, and regular handwashing. We repeated analyses within two sets of subgroups: participants recruited in clinic-based or mobile outreach testing venues, and participants who reported experiencing or not experiencing clinical symptoms within 2 weeks before testing. As secondary analyses, we also fit models defining pneumococcal carriage as *lytA* and *piaB*  $C_T$  <35.

To determine if associations varied according to pneumococcal density, we fit conditional logistic regression models partitioning pneumococcal carriage according to *lytA* and *piaB* C<sub>T</sub> in the ranges of 35-39.9, 30-34.9, and <30. We also fit models subset to participants carried pneumococci, within which we defined *lytA* and *piaB* C<sub>T</sub> as continuous quantitative covariates. To determine if SARS-CoV-2 abundance was associated with pneumococcal detection or density, we also fit regression models relating C<sub>T</sub> values (as continuous outcomes) for the SARS-CoV-2 N and E genes in saliva to pneumococcal detection. Each of these analyses adjusted for the covariates included in primary analyses.

Last, we sought to determine whether the association between recent SARS-CoV-2 exposure and risk of infection differed in association with pneumococcal carriage detection. We conducted analyses considering two distinct SARS-CoV-2 exposure definitions: self-reported contact with any individual experiencing acute upper respiratory symptoms ("suspected" exposure; expected to provide a sensitive albeit non-specific indicator), and notification of exposure to a confirmed SARS-CoV-2 case ("confirmed" exposure; expected to provide a specific indicator, although with low sensitivity since few exposures are notified). Conditional logistic regression models again defined strata by clinic-based or outreach test setting and controlled for all covariates included in primary analyses.

Multivariate-adjusted analyses were subset to individuals who participated in the primary study and thus completed the full telephone-based survey. Expanded data (including pneumococcal sub-study participants) are presented separately, where applicable, for analyses of pneumococcal and SARS-CoV-2 co-detection

6

without covariate adjustment. Missing covariate data where participants in the primary study responded to questions with "Don't know" or "Refuse" were populated by multiple imputation with five pseudo-datasets. We conducted analyses in R version 4.1.3.

## RESULTS

We enrolled 1,309 participants, including 1,115 in the primary study among farmworkers and 194 in the pneumococcal sub-study only. Saliva specimens were obtained from 1,306 individuals. We excluded 8 samples from individuals who participated in the primary study but did not meet eligibility criteria, and 15 samples due to quality concerns (insufficient volume, label mismatch, or contamination). Additionally, SARS-CoV-2 testing results were inconclusive or unavailable for 5 participants. Final analyses included 1,278 participants (1,095 in the primary study and 183 in the expanded sub-study). Of this sample, 564 and 714 participants were enrolled in clinic-based and mobile outreach testing venues, respectively, among whom 35.7% (199/558, excluding participants missing responses) and 25.4% (181/714), respectively, reported experiencing any solicited clinical symptoms within two weeks before testing (**Table S2**; **Table S3**).

Pneumococcal carriage prevalence was 9.2% (117/1,278) overall (11.2% [63/564] and 7.6% [54/714] in clinicbased and outreach testing, respectively; **Table 1**; **Table S4**). Within the clinic-based sample, prevalence of SARS-CoV-2 infection was 41.3% (26/63) among pneumococcal carriers and 13.8% (69/501) among noncarriers. Within the outreach sample, prevalence of SARS-CoV-2 infection was 11.1% (6/54) among pneumococcal carriers and 6.5% (43/660) among non-carriers. Similar patterns held in analyses defining pneumococcal carriage according to a *lytA* and *piaB*  $C_T$ <35 criterion, with SARS-CoV-2 detected among 34.0% (16/47) of pneumococcal carriers and 10.8% (113/1,048) of non-carriers. Higher point estimates of SARS-CoV-2 infection prevalence among pneumococcal carriers held within strata defined by age, sex, language, country of birth, community of residence, exposure to household crowding, income, education level, occupation, housing type, BMI, cigarette smoking, COVID-19 risk behaviors, and presence or absence of symptoms (**Table 2**).

7

Adjusted odds of SARS-CoV-2 infection were 2.73 (1.58-4.69) fold higher among pneumococcal carriers than non-carriers (**Table 3**). Corresponding aOR estimates among participants enrolled in clinic-based and outreach testing were 4.01 (2.08-7.75) and 0.95 (0.20-4.44), respectively. In expanded analyses including participants recruited into the pneumococcal sub-study, the unadjusted OR of SARS-CoV-2 infection associated with pneumococcal carriage in outreach-based test settings was 1.80 (0.73-4.45; **Table S5**), whereas associations within other strata more closely resembled those estimated within the primary study population.

Among participants within the primary study reporting any solicited symptoms, pneumococcal carriage was associated with 3.38 (1.35-8.40) fold higher adjusted odds of SARS-CoV-2 infection, while among participants reporting no symptoms, pneumococcal carriage was associated with 2.79 (1.26-6.24) fold higher adjusted odds of SARS-CoV-2 infection (**Table 3**). The strongest association between pneumococcal carriage and SARS-CoV-2 infection was apparent among symptomatic individuals enrolled in clinic-based testing (aOR=6.12 [1.87-20.5]). However, our analyses did not identify specific clinical symptoms associated with pneumococcal carriage or co-detection with SARS-CoV-2 (**Table S6**; **Table S7**).

Among pneumococcal carriers within the primary study with *piaB* C<sub>T</sub> values of 35-39.9, 30-34.9, and <30, prevalence of SARS-CoV-2 infection was 21.2% (11/52), 26.7% (8/30), and 38.1% (8/21; **Table 4**). Relative to participants who did not carry pneumococcus, adjusted odds of SARS-CoV-2 infection were 1.73 (0.80-3.74), 3.38 (1.35-8.40), and 5.77 (2.06-16.4) fold higher among those who carried pneumococci with *piaB* C<sub>T</sub> values of 35-39.9, 30-34.9, and <30, respectively. Defining *piaB* C<sub>T</sub> values as a continuous exposure, adjusted odds of SARS-CoV-2 infection increased 1.24 (1.00-1.55) fold for each 1-C<sub>T</sub> decrease among participants carrying pneumococci. In agreement with this pattern, the association of SARS-CoV-2 infection with pneumococcal carriage was strengthened when applying a more stringent definition of pneumococcal carriage as *lytA* and *piaB* C<sub>T</sub> <35 (aOR=4.53 [2.20-9.41] vs. 2.73 [1.58-4.69] for *lytA* and *piaB* C<sub>T</sub> <40; **Table S8**). Although C<sub>T</sub> values were positively correlated for *lytA* and *piaB*, we did not identify consistent associations of SARS-CoV-2 infection or with *lytA* C<sub>T</sub> values among pneumococcal carriers (**Table 4**; **Figure S1**). Likewise, C<sub>T</sub> values for the SARS-CoV-2 N and E genes in saliva specimens were not associated with pneumococcal detection or with *lytA* and *piaB* C<sub>T</sub> values (**Table S9**; **Figure S2**).

Among participants in the primary study who reported no suspected or notified SARS-CoV-2 exposure within 2 weeks before testing, prevalence of SARS-CoV-2 infection was 19.2% (15/78) among pneumococcal carriers and 7.9% (61/769) among non-carriers (**Table 5**). In contrast, 69.2% (9/13) of pneumococcal carriers and 26.1% (30/115) of non-carriers who reported suspected exposure tested positive for SARS-CoV-2 infection. The aOR of SARS-CoV-2 infection associated with suspected exposure were 7.64 (1.91-30.7) among pneumococcal carriers and 3.29 (1.94-5.59) among non-carriers. These differences in aOR point estimates held within analyses restricted to participants reporting such exposures in the home (aOR=6.66 [1.32-33.0] for carriers and 3.99 [2.06-7.67] for non-carriers) and workplace (aOR=6.25 [1.00-38.0] for carriers and 2.26 [1.17-4.38] for non-carriers). A similar pattern was apparent for participants who reported that they were notified of exposure to a confirmed COVID-19 case, although such analyses were underpowered due to the low frequency of notified exposures. The aOR of SARS-CoV-2 infection associated with notified exposure was 2.14 (0.28-16.0) among pneumococcal carriers and 0.83 (0.37-1.85) among non-carriers.

#### DISCUSSION

We identify a synergistic association between pneumococcal carriage and SARS-CoV-2 infection among adults tested in ambulatory clinics and community settings. This association was strongest among participants recruited through clinical SARS-CoV-2 testing and those experiencing acute COVID-19 symptoms. Among pneumococcal carriers, adjusted odds of concurrent SARS-CoV-2 infection increased 24% for each 1-unit decrease in *piaB* C<sub>7</sub>, indicating a density-dependent relationship. Last, the increase in odds of SARS-CoV-2 infection associated with recent exposure to a symptomatic individual was roughly two-fold higher among pneumococcal carriers as compared to non-carriers. Collectively, our findings are consistent with the hypothesis of interactions between pneumococci and SARS-CoV-2 in the upper respiratory tract.

In agreement with our findings, a prior study reported that pneumococcal carriage was detected more often among adults with asymptomatic or mild SARS-CoV-2 infection than among uninfected adults, and was

associated with reduced cellular and mucosal immune responses to SARS-CoV-2.<sup>19</sup> Similar interactions have been reported in studies involving other respiratory viruses,<sup>4-11</sup> which have further documented increased pneumococcal density in the upper airway during viral infection.<sup>5,7-9</sup> While cross-sectional epidemiologic studies cannot distinguish interaction mechanisms underlying these findings—such as pneumococcal outgrowth during viral infection, or facilitation of viral infection during pneumococcal carriage—several studies in mouse models have suggested facilitative interactions may be bidirectional. Challenge with wild-type influenza A virus or live attenuated influenza vaccine extended the duration of pneumococcal carriage in mice, regardless of whether exposure to pneumococci preceded or followed exposure to influenza.<sup>12</sup> Additionally, pneumococcal/SARS-CoV-2 coinfection was associated with enhanced mortality in mice, regardless of the order of challenge with SARS-CoV-2 and pneumococci.<sup>31</sup> Last, in humans, experimentally-induced pneumococcal colonization dampened mucosal responses to subsequent challenge with live attenuated influenza vaccine.<sup>13</sup>

In contrast to the observed associations of pneumococcal density with SARS-CoV-2 presence or absence, SARS-CoV-2 C<sub>T</sub> values were not associated with pneumococcal carriage or density in our study. This circumstance may owe to pronounced temporal variability in SARS-CoV-2 viral load over the course of infection.<sup>32</sup> Importantly, our study could not account for time since SARS-CoV-2 acquisition, which is a primary determinant of viral load and may have influenced the findings.

Associations of recent suspected or notified SARS-CoV-2 exposure with risk of infection were stronger among pneumococcal carriers than non-carriers in our study. As typical durations of pneumococcal carriage among adults exceed the 2-week recall period of this exposure,<sup>33</sup> pneumococcal colonization likely preceded SARS-CoV-2 exposure for most study participants with both pathogens detected. At least two interpretations of this finding are possible. First, our finding may signify heightened risk of SARS-CoV-2 infection, given exposure, in the context of nasopharyngeal inflammation induced by pneumococcal colonization. In support of this hypothesis, pre-existing pneumococcal carriage has been found to predict increased risk of new-onset of virus-associated acute respiratory infections among children.<sup>15</sup> In another study among children, pneumococcal carriage density was found to increase markedly with acquisition of RSV or rhinoviruses,<sup>34</sup> although such increases could also be driven by a loss of control of existing pneumococcal colonization following viral

10

acquisition.<sup>35</sup> An alternative interpretation may thus view our finding as an artifact of enhanced pneumococcal outgrowth associated with recent SARS-CoV-2 exposure and acquisition. If such outgrowth is transient in nature, higher pneumococcal density (and thus pneumococcal carriage detection) could be associated with more recent SARS-CoV-2 acquisition, thereby accounting for stronger associations between SARS-CoV-2 infection and exposure in the prior 2 weeks among individuals found to carry pneumococci. As our cross-sectional study design cannot distinguish between these hypotheses, longitudinal studies relating baseline pneumococcal carriage status to risk of subsequent viral acquisition are needed.

Our study has several limitations. Recruitment of farmworkers in low-income communities indicates that absolute estimates of prevalence of pneumococcal carriage and SARS-CoV-2 infection are not externally generalizable. Our data do not encompass potential social linkages among participants, who in some instances may have lived or worked together. As recruitment for this study occurred in summer and fall of 2020, cases in our study were not infected with recent SARS-CoV-2 variants of concern. While our analysis demonstrated density-dependent relationships between pneumococcal carriage and SARS-CoV-2 infection based on *piaB* C<sub>T</sub> values, these readings were taken following a culture enrichment step. Measures of bacterial abundance obtained prior to culture enrichment would be expected to better represent carriage density in the host, although previous studies have demonstrated strong correlations in pneumococcal C<sub>T</sub> values before and after culture enrichment.<sup>36,37</sup> Last, our study population was recruited in ambulatory care settings and outreach testing venues, and does not represent the full spectrum of COVID-19 disease severity including cases requiring hospital or intensive care unit admission. Observed associations should thus be interpreted as markers of pathogen interactions either in mild-to-moderate infections or at early stages in the clinical course, prior to severe disease progression.

Our findings corroborate several previous lines of evidence<sup>19-21,31</sup> suggesting a relationship exists between pneumococci and SARS-CoV-2 infection among adults. Whereas IPD incidence declined precipitously during the early COVID-19 pandemic, this pattern may have been driven, in part, by frequent antibiotic treatment of COVID-19 patients who would otherwise be at risk,<sup>17</sup> absent transmission of other viruses. Of note, non-bacteremic pneumococcal pneumonia and LRTI have persisted during the pandemic, and pneumococcal

antigen detection has been associated with increased disease severity among hospitalized COVID-19 cases.<sup>18</sup> Increased density may facilitate pneumococcal transmission during SARS-CoV-2 infection in addition to increasing individuals' risk of subsequent LRTI and IPD, absent antibiotic treatment.<sup>38,39</sup> Monitoring for severe co-infections involving SARS-CoV-2 and pneumococcus thus remains warranted as antimicrobial stewardship for COVID-19 cases improves. While vaccines now offer a primary prevention strategy for COVID-19, our results pinpoint interactions involving pneumococci in the upper airway as a component of SARS-CoV-2 natural history, resembling observations with other viruses. These findings may inform control strategies against polymicrobial infections.

# FUNDING

The study was supported by the Innovative Genomics Institute at the University of California, Berkeley; Pfizer, Inc. (grant 61775823 to JAL); and the National Institutes of Health (grants R24ES028529 and R24ESD30888 to NH).

## **CONFLICTS OF INTEREST**

JAL discloses receipt of grant funding and consulting honoraria from Pfizer, Inc.; grant funding and consulting honoraria from Merck, Sharp & Dohme; and consulting honoraria from VaxCyte, Inc.

## REFERENCES

- Weinberger DM, Klugman KP, Steiner CA, Simonsen L, Viboud C. Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data. PLOS Medicine, **2015**; 12:e1001776.
- 2. Walter ND, Taylor TH, Shay DK, et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis, **2010**; 50:175–83.

- Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis, **2008**; 198: 962– 70.
- Karppinen S, Teräsjärvi J, Auranen K, et al. Acquisition and transmission of *Streptococcus pneumoniae* are facilitated during rhinovirus infection in families with children. Am J Respir Crit Care Med, **2017**; 196:1172–80.
- Thors V, Christensen H, Morales-Aza B, et al. High-density bacterial nasal carriage in children is transient and associated with respiratory viral infections: implications for transmission dynamics. Pediatr Infect Dis J, 2019; 38:533–8.
- De Steenhuijsen Piters WAA, Heinonen S, Hasrat R, et al. Nasopharyngeal microbiota, host transcriptome, and disease severity in children with respiratory syncytial virus infection. Am J Respir Crit Care Med, **2016**; 194: 1104–15.
- Baggett HC, Watson NL, Deloria Knoll M, et al. Density of upper respiratory colonization with *Streptococcus pneumoniae* and its role in the diagnosis of pneumococcal pneumonia among children aged <5 years in the PERCH study. Clin Infect Dis, **2017**; 64:S317–27.
- 8. DeMuri GP, Gern JE, Eickhoff JC, Lynch SV, Wald ER. Dynamics of bacterial colonization with *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* during symptomatic and asymptomatic viral upper respiratory tract infection. Clin Infect Dis, **2018**; 66:1045–53.
- Miellet WR, van Veldhuizen J, Nicolaie MA, et al. Influenza-like illness exacerbates pneumococcal carriage in older adults. Clin Infect Dis, **2021**; 73:e2680–9.
- 10. Park DE, Higdon MM, Prosperi C, et al. Upper respiratory tract co-detection of human endemic coronaviruses and high-density pneumococcus associated with increased severity among HIV-uninfected children under 5 years old in the PERCH Study. Pediatr Infect Dis J, **2021**; 40:503–12.
- De Lastours V, Malosh R, Ramadugu K, et al. Co-colonization by *Streptococcus pneumoniae* and *Staphylococcus aureus* in the throat during acute respiratory illnesses. Epidemiol Infect, **2016**; 144:3507–19.
- 12. Mina MJ, McCullers JA, Klugman KP. Live attenuated influenza vaccine enhances colonization of *Streptococcus pneumoniae* and *Staphylococcus aureus* in mice. mBio, **2014**; 5:e01040-13.

- Carniel BF, Marcon F, Rylance J, et al. Pneumococcal colonization impairs mucosal immune responses to live attenuated influenza vaccine. JCI Insight, **2021**; 6:141088.
- Rylance J, de Steenhuijsen Piters WAA, Mina MJ, et al. Two randomized trials of the effect of live attenuated influenza vaccine on pneumococcal colonization. Am J Respir Crit Care Med, **2019**; 199:1160–3.
- Howard LM, Zhu Y, Griffin MR, et al. Nasopharyngeal pneumococcal density during asymptomatic respiratory virus infection and risk for subsequent acute respiratory illness. Emerg Infect Dis, **2019**; 25:2040–7.
- 16. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect, **2020**; 81:266–75.
- 17. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect, **2021**; 27:520–31.
- Watkins AE, Glick LR, Ott IM, et al. Detection of pneumococcus during hospitalization for SARS-CoV-2. medRxiv, 2022; doi:10.1101/2022.07.13.22277607.
- 19. Mitsi E, Reiné J, Urban BC, et al. *Streptococcus pneumoniae* colonization associates with impaired adaptive immune responses against SARS-CoV-2. J Clin Invest, **2022**; 132:e157124.
- 20. Amin-Chowdhury Z, Aiano F, Mensah A, et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on invasive pneumococcal disease and risk of pneumococcal coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): prospective national cohort study, England. Clin Infect Dis, **2021**; 72:e65–75.
- Lewnard JA, Bruxvoort KJ, Fischer H, et al. Prevention of coronavirus disease 2019 among older adults receiving pneumococcal conjugate vaccine suggests interactions between *Streptococcus pneumoniae* and severe acute respiratory syndrome coronavirus 2 in the respiratory tract. J Infect Dis, **2022**; 225:1710–20.
- 22. Madhi SA, Klugman KP, Vaccine Trialist Group. A role for *Streptococcus pneumoniae* in virusassociated pneumonia. Nat Med, **2004**; 10:811–3.
- Madhi SA, Ludewick H, Kuwanda L, et al. Pneumococcal coinfection with human metapneumovirus. J Infect Dis, **2006**; 193:1236–43.

- Nunes MC, Cutland CL, Klugman KP, Madhi SA. Pneumococcal conjugate vaccine protection against coronavirus-associated pneumonia hospitalization in children living with and without HIV. mBio, 2021; 12:e02347-20.
- 25. Lewnard JA, Bruxvoort KJ, Hong VX, et al. Effectiveness of pneumococcal conjugate vaccination against virus-associated lower respiratory tract infection among adults: a case-control study. J Infect Dis, **2022**; doi:10.1093/infdis/jiac098.
- 26. Lewnard JA, Mora AM, Nkwocha O, et al. Prevalence and clinical profile of severe acute respiratory syndrome coronavirus 2 infection among farmworkers, California, USA, June-November 2020. Emerg Infect Dis, **2021**; 27:1330–42.
- 27. Mora AM, Lewnard JA, Kogut K, et al. Risk factors associated with SARS-CoV-2 infection among farmworkers in Monterey County, California. JAMA Netw Open, **2021**; 4:e2124116.
- 28. Mora AM, Lewnard JA, Rauch S, et al. Impact of COVID-19 pandemic on California Farmworkers' mental health and food security. J Agromedicine, **2022**; 27:303–14.
- 29. Villarejo D, Wadsworth G. Farmworker housing study and action plan for Salinas Valley and Pajaro Valley. Available from: https://www.co.monterey.ca.us/home/showdocument?id=63729. Accessed 4 October, 2022.
- 30. Wyllie AL, Rümke LW, Arp K, et al. Molecular surveillance on *Streptococcus pneumoniae* carriage in non-elderly adults; little evidence for pneumococcal circulation independent from the reservoir in children. Sci Rep, **2016**; 6:34888.
- 31. Barman TK, Singh AK, Bonin JL, Nafiz TN, Salmon SL, Metzger DW. Lethal synergy between SARS-CoV-2 and Streptococcus pneumoniae in hACE2 mice and protective efficacy of vaccination. JCI Insight, 2022; 7:e159422.
- 32. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and metaanalysis. Lancet Microbe, **2021**; 2:e13–22.
- 33. Almeida ST, Paulo AC, Froes F, de Lencastre H, Sá-Leão R. Dynamics of pneumococcal carriage in adults: a new look at an old paradigm. J Infect Dis, **2021**; 223:1590–600.

- Morpeth SC, Munywoki P, Hammitt LL, et al. Impact of viral upper respiratory tract infection on the concentration of nasopharyngeal pneumococcal carriage among Kenyan children. Sci Rep, **2018**; 8:11030.
- 35. Jochems SP, Marcon F, Carniel BF, et al. Inflammation induced by influenza virus impairs human innate immune control of pneumococcus. Nat Immunol, **2018**; 19:1299–308.
- 36. Nikolaou E, Jochems SP, Mitsi E, et al. Experimental human challenge defines distinct pneumococcal kinetic profiles and mucosal responses between colonized and non-colonized adults. mBio, 2021; 12:e02020-20.
- 37. Wyllie AL, Chu MLJN, Schellens MHB, et al. *Streptococcus pneumoniae* in saliva of Dutch primary school children. PLoS One, **2014**; 9:e102045.
- 38. Wolter N, Tempia S, Cohen C, et al. High nasopharyngeal pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal pneumonia. Clin Infect Dis, **2014**; 210:1649–57.
- 39. Weinberger DM, Grant LR, Steiner CA, et al. Seasonal drivers of pneumococcal disease incidence: impact of bacterial carriage and viral activity. Clin Infect Dis, **2014**; 58:188–94.

# Table 1: Co-detection of SARS-CoV-2 and pneumococcus within the primary and expanded study populations. Pneumococcal detection Population SARS-CoV-2 infected/Total, n (%)

threshold	Population							
		All testir	ng venues	Clinic-bas	ed testing	Outreach-ba	ased testing	
		Pneumococcus detected	Pneumococcus not detected	Pneumococcus detected	Pneumococcus not detected	Pneumococcus detected	Pneumococcus not detected	
<i>lytA</i> C <i></i> <sub>7</sub> <40 and <i>piaB</i> C <sub>7</sub> <40								
	Primary study participants	27/103 (26.2)	102/992 (10.3)	25/60 (41.7)	69/489 (14.1)	2/43 (4.7)	33/503 (6.6)	
	Expanded dataset, including pneumococcal sub- study participants	32/117 (27.4)	112/1,161 (9.6)	26/63 (41.3)	69/501 (13.8)	6/54 (11.1)	43/660 (6.5)	
<i>lytA</i> C <sub>T</sub> <35 and <i>piaB</i> C <sub>T</sub> <35								
	Primary study participants	16/47 (34.0)	113/1,048 (10.8)	15/30 (50.0)	79/519 (15.2)	1/17 (5.9)	34/529 (6.4)	
	Expanded dataset, including pneumococcal sub- study participants	19/53 (35.8)	125/1,225 (10.2)	16/31 (51.6)	79/533 (14.8)	3/22 (13.6)	46/692 (6.6)	

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens. Pneumococcal detection was defined as C<sub>7</sub> values below 40 for both the *lytA* and *piaB* targets.

	Table 2: SARS-CoV-2 infection within the	primary study	population, by	pneumococcal carriage status.
--	--	---------------	----------------	-------------------------------

Attribute				n/N	(%)		
		All testin Pneumococcus	<i>g venues</i> Pneumococcus		ed testing Pneumococcus	<i>Outreach-b</i> <u>Pneumococcus</u>	ased testing Pneumococcus
		detected	not detected	detected	not detected	detected	not detected
Age							
	18-29 years	6/29 (20.7)	27/243 (11.1)	5/16 (31.2)	16/120 (13.3)	1/13 (7.7)	11/123 (8.9)
	30-39 years	10/37 (27.0)	22/234 (9.4)	10/22 (45.5)	15/112 (13.4)	0/15 (0.0)	7/122 (5.7)
	40-49 years	9/26 (34.6)	33/263 (12.5)	8/16 (50.0)	23/140 (16.4)	1/10 (10.0)	10/123 (8.1)
Sex	≥50 years	2/11 (18.2)	20/252 (7.9)	2/6 (33.3)	15/117 (12.8)	0/5 (0.0)	5/135 (3.7)
Sex	Male	12/45 (26.7)	50/477 (10.5)	12/26 (46.2)	35/230 (15.2)	0/19 (0.0)	15/247 (6.1)
	Female	15/58 (25.9)	52/515 (10.1)	13/34 (38.2)	34/259 (13.1)	2/24 (8.3)	18/256 (7.0)
Language spoken at home	remale	15/50 (25.9)	52/515 (10.1)	13/34 (30.2)	34/239 (13.1)	2/24 (0.3)	10/230 (7.0)
Language spoken at nome	Spanish	15/68 (22.1)	88/863 (10.2)	14/35 (40.0)	57/411 (13.9)	1/33 (3.0)	31/452 (6.9)
	Indigenous language	11/29 (37.9)	13/79 (16.5)	11/23 (47.8)	12/60 (20.0)	0/6 (0.0)	1/19 (5.3)
	English	1/6 (16.7)	1/50 (2.0)	0/2 (0.0)	0/18 (0.0)	1/4 (25.0)	1/32 (3.1)
Country of birth	g	.,,		0,2 (0.0)	0,10 (010)		., •= (•)
	Mexico	24/87 (27.6)	86/826 (10.4)	23/52 (44.2)	59/422 (14.0)	1/35 (2.9)	27/404 (6.7)
	United States	2/13 (15.4)	11/127 (8.7)	1/5 (20.0)	5/42 (11.9) <sup>′</sup>	1/8 (12.5)	6/85 (7.1)
	Other	1/3 (33.3)	5/39 (12.8)	1/3 (33.3)	5/25 (20.0)́	Ò/O	0/14 (0.0)
Community of residence							
	Salinas	6/39 (15.4)	43/443 (9.7)	4/21 (19.0)	26/234 (11.1)	2/18 (11.1)	17/209 (8.1)
	Greenfield	17/38 (44.7)	38/270 (14.1)	17/28 (60.7)	35/182 (19.2)	0/10 (0.0)	3/88 (3.4)
	Other	4/26 (15.4)	21/279 (7.5)	4/11 (36.4)	8/73 (11.0)	0/15 (0.0)	13/206 (6.3)
Household crowding							
	0-2 persons/bedroom	12/53 (22.6)	64/642 (10.0)	11/30 (36.7)	42/296 (14.2)	1/23 (4.3)	22/346 (6.4)
	2.1 to 4 persons/bedroom	11/40 (27.5)	33/320 (10.3)	10/22 (45.5)	24/178 (13.5)	1/18 (5.6)	9/142 (6.3)
	>4 persons/bedroom	4/8 (50.0)	5/29 (17.2)	4/6 (66.7)	3/15 (20.0)	0/2 (0.0)	2/14 (14.3)
Exposure to children at home	No children et home	4/40 (00 0)	20/259 (11.2)	4/7 (57 4)	20/116 (17.2)	0/11 (0.0)	0/140 (6.2)
	No children at home	4/18 (22.2)	29/258 (11.2)	4/7 (57.1)	20/116 (17.2)	0/11 (0.0)	9/142 (6.3)
	Any child <5 years old Children 5-18 years old only	10/45 (22.2) 13/40 (32.5)	33/361 (9.1)	9/27 (33.3)	20/187 (10.7)	1/18 (5.6)	13/174 (7.5) 11/187 (5.9)
Household income	Children 5-18 years old only	13/40 (32.5)	40/373 (10.7)	12/26 (46.2)	29/186 (15.6)	1/14 (7.1)	11/10/ (5.9)
nousenoid meome	<\$25,000	14/53 (26.4)	55/494 (11.1)	14/33 (42.4)	37/249 (14.9)	0/20 (0.0)	18/245 (7.3)
	\$25,000-34,999	6/21 (28.6)	16/236 (6.8)	5/11 (45.5)	9/98 (9.2)	1/10 (10.0)	7/138 (5.1)
	\$35,000-49,999	4/13 (30.8)	21/146 (14.4)	4/8 (50.0)	17/75 (22.7)	0/5 (0.0)	4/71 (5.6)
	≥\$50,000	1/3 (33.3)	7/73 (9.6)	0/1 (0.0)	4/45 (8.9)	1/2 (50.0)	3/28 (10.7)
Education level	+;			()		()	
	No formal schooling	5/8 (62.5)	7/54 (13.0)	5/8 (62.5)	6/40 (15.0)	0/0	1/14 (7.1)
	Primary school complete	11/40 (27.5)	44/379 (11.6)	10/22 (45.5)	32/198 (16.2)	1/18 (5.6)	12/181 (6.6)
	Junior high school complete	7/43 (16.3)	30/330 (9.1)	7/24 (29.2)	22/158 (13.9)	0/19 (0.0)	8/172 (4.7)
	High school complete	4/12 (33.3)	21/228 (9.2)	3/6 (50.0)	9/92 (9.8)	1/6 (16.7)	12/136 (8.8)
Agricultural occupation							
	Fieldwork	25/88 (28.4)	80/728 (11.0)	24/51 (47.1)	54/355 (15.2)	1/37 (2.7)	26/373 (7.0)
	Non-fieldwork	1/14 (7.1)	20/255 (7.8)	0/8 (0.0)	13/125 (10.4)	1/6 (16.7)	7/130 (5.4)
Housing type							
	Single-family house	16/51 (31.4)	52/467 (11.1)	15/37 (40.5)	35/282 (12.4)	1/14 (7.1)	17/185 (9.2)
	Apartment	10/40 (25.0)	40/432 (9.3)	9/19 (47.4)	26/169 (15.4)	1/21 (4.8)	14/263 (5.3)
	Trailer/mobile home Hotel/motel	0/5 (0.0)	3/38 (7.9)	0/3 (0.0)	2/20 (10.0)	0/2 (0.)	1/18 (5.6)
	Other	1/6 (16.7)	5/31 (16.1)	1/1 (100) 0/0	5/7 (71.4)	0/5 (0.0)	0/24 (0.0)
Body mass index	Oulei	0/1 (0.0)	2/24 (8.3)	0/0	1/11 (9.1)	0/1 (0.0)	1/13 (7.7)
Body mass index	<25	3/14 (21.4)	16/182 (8.8)	3/5 (60.0)	12/101 (11.9)	0/9 (0.0)	4/81 (4.9)
	25 to <30 (overweight)	12/41 (29.3)	36/372 (9.7)	12/25 (48.0)	21/178 (11.8)	0/16 (0.0)	15/194 (7.7)
	≥30 (obese)	9/45 (20.0)	46/414 (11.1)	7/27 (25.9)	33/193 (17.1)	2/18 (11.1)	13/221 (5.9)
		0/40 (20.0)		1/21 (20.0)	00,100 (17.1)	2/10 (11.1)	10/221 (0.0)

Cigarette smoking							
	Never smoked	22/87 (25.3)	87/800 (10.9)	20/50 (40.0)	58/394 (14.7)	2/37 (5.4)	29/406 (7.1)
	Former smoking	5/13 (38.5)	12/145 (8.3)	5/9 (55.6)	10/77 (13.0)	0/4 (0.0)	2/68 (2.9)
	Current smoking	0/3 (0.0)	3/46 (6.5)	0/1 (0.0)	1/17 (5.9)	0/2 (0.0)	2/29 (6.9)
COVID-19 risk-mitigating	Ũ	· · · ·	· · /	× ,	( )	· · ·	<b>、</b> ,
behaviors							
	Mask wearing indoors	27/95 (28.4)	98/914 (10.7)	25/56 (44.6)	66/449 (14.7)	2/39 (5.1)	32/465 (6.9)
	Avoidance of indoor social gatherings in	25/98 (25.5)	93/935 (9.9)	23/57 (40.4)	65/462 (14.1)	2/41 (4.9)	28/473 (5.9)
	prior 2 weeks						
	Regular handwashing	26/97 (26.8)	100/965 (10.4)	24/57 (42.1)	67/474 (14.1)	2/40 (5.0)	33/491 (6.7)
Clinical status	ů ů	. ,	. ,	, , , , , , , , , , , , , , , , , , ,		. ,	. ,
	Any symptoms in prior 2 weeks	16/30 (53.3)	59/261 (22.6)	15/23 (65.2)	45/167 (26.9)	1/7 (14.3)	14/94 (14.9)
	No symptoms in prior 2 weeks	11/72 (15.3)	43/726 (5.9)	10/36 (27.8)	24/317 (7.6)	1/36 (2.8)	19/409 (4.6)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens. Pneumococcal detection was defined as C<sub>T</sub> values below 40 for both the *lytA* and *piaB* targets. Data may not add to column totals in case of missing data on any question.

# Table 3: Association of SARS-CoV-2 infection with pneumococcal carriage detection within the primary study population.

Participants	All testing	g venues	Clinic-bas	Outreach-based testing		
	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)
Total sample	2.94 (1.79, 4.81)	2.73 (1.58, 4.69)	4.33 (2.45, 7.68)	4.01 (2.08, 7.75)	0.69 (0.16, 3.06)	0.95 (0.20, 4.44)
Any symptoms in prior two weeks	3.54 (1.62, 7.79)	3.38 (1.35, 8.40)	4.86 (1.95, 12.2)	6.12 (1.87, 20.5)		
No symptoms in prior two weeks	2.74 (1.35, 5.62)	2.79 (1.26, 6.24)	4.61 (2.01, 10.7)	5.63 (1.91, 16.2)	0.58 (0.08, 4.53)	0.78 (0.09, 6.65)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio; CI: confidence interval. Pneumococcal detection was defined as C<sub>T</sub> values below 40 for both the *lytA* and *piaB* targets.

# Table 4: Association of SARS-CoV-2 infection with *lytA* and *piaB*Cc<sub>T</sub> values in culture-enriched saliva.

qPCR target	Carriage status and Ct value for indicated qPCR target	SARS-Co	/-2 infected/Total, %	Odds ratio (95% CI), computed within the primary study population		
		Primary study participants	Expanded dataset, including pneumococcal sub-study participants	Unadjusted	Adjusted	
lytA						
-	No pneumococcal carriage	102/992 (10.3)	112/1,161 (9.6)	ref.	ref.	
	35-39.9 (with <i>piaB</i> C⊤ <40)	5/17 (29.4)	6/21 (28.6)	3.66 (1.23, 10.8)	2.88 (0.86, 9.74)	
	30-34.9 (with <i>piaB</i> C <sub>T</sub> <40)	7/31 (22.6)	7/32 (21.9)	2.33 (0.96, 5.63)	2.26 (0.88, 5.84)	
	<30 (with <i>piaB</i> C <i>τ</i> <40)	15/55 (27.3)	19/64 (29.7)	3.11 (1.64, 5.88)	2.95 (1.47, 5.92)	
	Continuous OR—per 1-unit decrease in <i>lytA</i> C <sub>7</sub> , among pneumococcal carriers	27/103 (26.2)	32/117 (27.4)	0.97 (0.88, 1.07)	0.94 (0.81, 1.09)	
piaB						
	No pneumococcal carriage	102/992 (10.3)	112/1,161 (9.6)	ref.	ref.	
	35-39.9 (with <i>lytA</i> C <sub>7</sub> <40)	11/52 (21.2)	13/58 (22.4)	2.24 (1.10, 4.58)	1.73 (0.80, 3.74)	
	30-34.9 (with <i>lytA</i> C <sub>T</sub> <40)	8/30 (26.7)	9/33 (27.3)	2.94 (1.26, 6.90)	3.38 (1.35, 8.40)	
	<30 (with <i>lytA</i> $C_T$ <40)	8/21 (38.1)	10/26 (38.5)	5.03 (1.98, 12.8)	5.77 (2.06, 16.4)	
	Continuous OR—per 1-unit decrease in <i>piaB</i> c <sub>7</sub> , among pneumococcal carriers	27/103 (26.2)	32/117 (27.4)	1.07 (0.96, 1.19)	1.24 (1.00, 1.55)	

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio; CI: confidence interval. Pneumococcal detection was defined as C<sub>T</sub> values below 40 for both the *lytA* and *piaB* targets.

# Table 5: Association of SARS-CoV-2 infection with recent exposure among individuals carrying and those not carrying pneumococcus.

Exposure status	SARS-CoV-2 infected/Total (%), by pneumococcal carriage status		Pneumococcal ca	rriage not detected	Pneumococcal carriage detected	
	Pneumococcus detected	Pneumococcus not detected	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
No contact with symptomatic individual in prior two weeks	15/78 (19.2)	61/769 (7.9)	ref.	ref.	ref.	ref.
Contact with symptomatic individual in prior two weeks—Any	9/13 (69.2)	30/115 (26.1)	3.21 (1.95, 5.26)	3.29 (1.94, 5.59)	7.25 (1.95, 26.8)	7.64 (1.91, 30.7)
Contact with symptomatic individual in prior two weeks—Home	6/9 (66.7)	18/61 (29.5)	3.82 (2.10, 6.99)	3.99 (2.06, 7.67)	5.35 (1.22, 24.0)	6.66 (1.32, 33.0)
Contact with symptomatic individual in prior two weeks-Work	5/7 (71.4)	16/63 (25.4)	2.49 (1.33, 4.63)	2.26 (1.17, 4.38)	6.34 (1.14, 34.8)	6.25 (1.00, 38.0)
No notification of contact with confirmed case in prior two weeks	25/98 (25.5)	94/922 (10.2)	ref.	ref.	ref.	ref.
Notification of contact with confirmed case in prior two weeks	2/5 (40.0)	8/70 (11.4)	0.90 (0.42, 1.98)	0.83 (0.37, 1.85)	2.51 (0.37, 17.1)	2.14 (0.28, 16.0)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio; CI: confidence interval. Pneumococcal detection was defined as C<sub>T</sub> values below 40 for both the *lytA* and *piaB* targets.

# Text S1: Supplemental laboratory methods.

Culture enrichment and bacterial DNA extraction. Raw saliva specimens were frozen at -20°C after collection and thereafter stored at -80°C. Samples were thawed on ice after arrival at the laboratory; after thawing, 100µL of unprocessed saliva was spread onto trypticase soy agar supplemented with 7% sheep's blood and 5mg/L gentamicin. Plates were then incubated at 37°C with 5% CO<sub>2</sub> for 14-19 hours. Bacterial arowth was harvested into 2.1mL of 10% glycerol brain-heart infusion broth (BHI), and stored at -20°C. Specimen DNA was extracted from 200µL of the culture-enriched sample after being thawed, vortexed, and transferred to sterile 1.5mL Eppendorf tubes prefilled with freshly prepared lysis buffer (40mg/mL lysozyme and 75U/mol mutanolysin) for 90 minutes' incubation at 37°C. Next, 20µL of protease K was added to each sample, followed by incubation for 60 minutes at 56°C. Subsequent extraction steps used the QIAGEN DNeasy Blood and Tissue Kit (QIAGEN; Hilden, Germany) following manufacturer's instructions. Briefly, DNA was eluted into 50µL elution buffer and stored at -20°C; samples with DNA concentration <20ng/µL, measured using a spectrophotometer, underwent a second extraction. Positive and negative control DNA was extracted from pure cultures of S. pneumoniae by the boilate method. Briefly, colonies grown overnight on a TSA-GENT plate were extracted and suspended in 60µL nuclease-free water, then placed into a water bath heated to 100°C. Samples were boiled for 10 minutes before being centrifuged for 10 minutes at 14,000 rpm. Nucleic acid concentration was measured using a spectrophotometer following removal of the supernatant. Control DNA was diluted with nuclease-free water to a concentration of 50ng/µL.

**Detection of lytA and piaB in culture-enriched specimens.** Positive control samples used a diluted series of the reference strain ATCC 49619, while negative controls were DNA from human saliva previously characterized as negative for *S. pneumoniae*, and DNA from *E. coli* reference strain ATCC 25922. Gene detection via qPCR was conducted with primer concentrations at 400nM and 300nM, and probe concentrations at 75nM and 200nM, for *lytA* and *piaB*, respectively. All qPCR assays tested 2.5µL of DNA template in 25µL reactions. Thermal cycling conditions were as follows: 3 minutes at 95°C for initial denaturation; 15 seconds at 98°C for denaturation; and 30 seconds at 60°C for annealing.

**Detection of SARS-CoV-2 in saliva samples.** Prior to measuring  $C_T$  values, all samples were subjected to a freeze-thaw cycle for aliquoting. In addition, saliva samples from participants with a positive diagnostic test result were heat inactivated at 56°C for 30 minutes for safety purposes. Saliva samples were defrosted on ice for approximately 30 minutes. Once defrosted, raw saliva was pipetted into Omnigene tubes (Omnigene OM-505) and an equal volume of Omnigene solution was added. Samples were then extracted as previously described.<sup>1</sup> Briefly, samples were incubated at 50°C for 2 hours, followed by 30 minutes' incubation at 65°C. Using a Hamilton Microlab STARlet, 112µL of processed saliva was combined with 338µL of 2x DNA/RNA Shield (Zymo; R1200). RNA was extracted with the MagMax Viral Pathogen Kit (ThermoFisher; A42352) using a Hamilton Vantage. Viral N and E genes, and human RNaseP were amplified using the LuNER assay, as previously described.<sup>2</sup> Positive and negative controls were included for extraction and qPCR and were used to establish plate validity. RNaseP amplification within each sample was used to determine sample validity. Samples were re-extracted and re-amplified as needed for final  $C_T$  values.

# Supplemental references:

- 1. Hamilton JR, Stah EC, Tsuchida CA, et al. Robotic RNA extraction for SARS-CoV-2 surveillance using saliva samples. *PLOS ONE* 2021; doi:10.1371/journal.pone.02555690.
- 2. Stahl EC, Tsuchida CA, Hamilton JR, et al. IGI-LuNER: single-well multiplexed RT-qPCR test for SARS-CoV-2. *medRxiv* 2020; doi:10.1101/2020.12.10.20247338.

# Table S1: Gene targets for molecular detection of pneumococci.

Gene	Nucleotide sequence
lytA	ACGCAATCTAGCAGATGAAGCAGGTTTGCCGAAAACGCTTGATACAGGGAGTTTAGCTGGAATTAAAACGCACGA
piaB	CATTGGTGGCTTAGTAAGTGCAATTTTTGTATACGCGATTGCTGTAAGCGGAAAAGCAGGCCTTACCCCTATAAAACTTGCCTTATCAG GAACTTGTGTTAGTA

Attribute	· · · ·			n/N		<u> </u>	
			sample		sample		h sample
		Pneumococcus	Pneumococcus	Pneumococcus	Pneumococcus	Pneumococcus	Pneumococcus
		<u>detected</u>	not detected	<u>detected</u>	not detected	<u>detected</u>	not detected
		N=103	N=992	<i>N</i> =60	N=489	N=43	N=503
Age	40.00			40 (00 7)		40 (00 0)	
	18-29 years	29 (28.2)	243 (24.5)	16 (26.7)	120 (24.5)	13 (30.2)	123 (24.5)
	30-39 years	37 (35.9)	234 (23.6)	22 (36.7)	112 (22.9)	15 (34.9)	122 (24.3)
	40-49 years	26 (25.2)	263 (26.5)	16 (26.7)	140 (28.6)	10 (23.3)	123 (24.5)
	≥50 years	11 (10.7)	252 (25.4)	6 (10.0)	117 (23.9)	5 (11.6)	135 (26.8)
Sex							
	Male	45 (43.7)	477 (48.1)	26 (43.3)	230 (47.0)	19 (44.2)	247 (49.1)
	Female	58 (56.3)	515 (51.9)	34 (56.7)	259 (53.0)	24 (55.8)	256 (50.9)
Language spoken at home	9						
	Spanish	68 (66.0)	863 (87.0)	35 (58.3)	411 (84.0)	33 (76.7)	452 (89.9)
	Indigenous language	29 (28.2)	78 (8.0)	23 (38.3)	60 (12.3)	6 (14.0)	19 (3.8)
	English	6 (5.8)	50 (5.0)	2 (3.3)	18 (3.7)	4 (9.3)	32 (6.4)
Country of birth	-		. ,	. ,	. ,	. ,	
-	Mexico	87 (84.5)	826 (83.3)	52 (86.7)	422 (86.3)	35 (81.4)	404 (80.3)
	United States	13 (12.6)	127 (12.8)	5 (8.3)	42 (8.6)	8 (18.6)	85 (16.9)
	Other	3 (2.9)	39 (3.9)	3 (5.0)	25 (5.1)	0 (0.0)	14 (2.8)
Community of residence		- ()	()	- ()	()	- ()	()
	Salinas	39 (37.9)	443 (44.7)	21 (35.0)	234 (47.9)	18 (41.9)	209 (41.6)
	Greenfield	38 (36.9)	270 (27.2)	28 (46.7)	182 (37.2)	10 (23.3)	88 (17.5)
	Other	26 (25.2)	279 (28.1)	11 (18.3)	73 (14.9)	15 (34.9)	206 (41.0)
Household crowding		20 (20:2)	210 (20.1)	11 (10.0)	10 (11.0)	10 (01.0)	200 (11.0)
······································	0-2 persons/bedroom	53 (52.5)	642 (64.8)	30 (51.7)	296 (60.5)	23 (53.5)	346 (68.9)
	2.1 to 4 persons/bedroom	40 (39.6)	320 (32.3)	22 (37.9)	178 (36.4)	18 (41.9)	142 (28.3)
	>4 persons/bedroom	8 (7.9)	29 (2.9)	6 (10.3)	15 (3.1)	2 (4.7)	14 (2.8)
Exposure to children at ho		0(1.3)	20 (2.0)	0 (10.0)	10 (0.1)	2 (4.7)	14 (2.0)
	No children at home	18 (17.5)	258 (26.0)	7 (11.7)	116 (23.7)	11 (25.6)	142 (28.2)
	Any child <5 years old	45 (43.7)	361 (36.4)	27 (45.0)	187 (38.2)	18 (41.9)	174 (34.6)
	Children 5-18 years old only	40 (38.8)	373 (37.6)	26 (43.3)	186 (38.0)	314 (32.6)	187 (37.2)
Household income	Children 5-10 years old only	40 (30.0)	575 (57.0)	20 (43.3)	100 (30.0)	514 (52.0)	107 (37.2)
nousenoid income	<\$25,000	53 (51.5)	494 (49.8)	33 (55.0)	249 (50.9)	20 (46.5)	245 (48.7)
	\$25,000-34,999	21 (20.4)	236 (23.8)	11 (18.3)	98 (20.0)	10 (23.3)	138 (27.4)
	\$35,000-49,999	13 (12.6)	146 (14.7)	8 (13.3)	75 (15.3)	5 (11.6)	71 (14.1)
					( )	· · ·	
Education level	≥\$50,000	3 (2.9)	73 (7.4)	1 (1.7)	45 (9.2)	2 (4.7)	28 (5.6)
Education level	No formal schooling	0 (7 0)	54 (5.4)	8 (13.3)	40 (8.2)	0 (0.0)	14 (2.0)
	0	8 (7.8) 40 (38.8)			· · ·		14 (2.8)
	Primary school complete		379 (38.2)	22 (36.7)	198 (40.6)	18 (41.9)	181 (36.0)
	Junior high school complete	43 (41.7)	330 (33.3)	24 (40.0)	158 (32.4)	19 (44.2)	172 (34.2)
	High school complete	12 (11.7)	228 (23.0)	6 (10.0)	92 (18.9)	6 (14.0)	136 (27.0)
Agricultural occupation	<b>F</b> ieldssents	00 (00 0)	700 (74 4)	F4 (00 4)	255 (74.0)	27 (00 0)	070 (74 0)
	Fieldwork	88 (86.3)	728 (74.1)	51 (86.4)	355 (74.0)	37 (86.0)	373 (74.2)
	Non-fieldwork	14 (13.7)	255 (25.9)	8 (13.6)	125 (26.0)	6 (14.0)	130 (25.8)
Housing type						( ( ( ) ) )	
	Single-family house	51 (49.5)	467 (47.1)	37 (61.7)	582 (57.7)	14 (32.6)	185 (36.8)
	Apartment	40 (38.8)	432 (43.5)	19 (31.7)	169 (34.6)	21 (48.8)	263 (52.3)
	Trailer/mobile home	5 (4.9)	38 (3.8)	3 (5.0)	20 (4.1)	2 (4.7)	18 (3.6)
	Hotel/motel	6 (5.8)	31 (3.1)	1 (1.7)	7 (1.4)	5 (11.6)	24 (4.8)
	Other						
Body mass index							
	<25	14 (14.0)	182 (18.8)	5 (8.8)	101 (21.4)	9 (20.9)	81 (16.3)
	25 to <30 (overweight)	41 (41.0)	372 (38.4)	25 (43.9)	178 (37.7)	16 (37.2)	194 (39.1)

Cigorotto omoking	≥30 (obese)	45 (45.0)	414 (42.8)	27 (47.4)	193 (40.9)	18 (41.9)	221 (44.6)
Cigarette smoking	Never smoked	87 (84.5)	800 (80.7)	50 (83.3)	394 (80.7)	37 (86.0)	406 (80.7)
	Former smoking	13 (12.6)	145 (14.6)	9 (15.0)	77 (15.8)	4 (9.3)	68 (13.5)
	Current smoking	3 (2.9)	46 (4.6)	1 (1.7)	17 (3.5)	2 (4.7)	29 (5.8)
COVID-19 risk behaviors	-						
	Inconsistent mask wearing indoors	8 (7.8)	78 (7.9)	4 (6.7)	40 (8.2)	4 (9.3)	38 (7.6)
	Indoor social gathering in prior 2 weeks	5 (4.9)	55 (5.6)	3 (5.0)	26 (5.3)	2 (4.7)	29 (5.8)
	Lack of regular handwashing	6 (5.8)	27 (2.7)	3 (5.0)	15 (3.1)	3 (7.0)	12 (2.4)
Clinical status				. ,	. ,		
	Current SARS-CoV-2 infection	27 (26.2)	102 (10.3)	25 (41.7)	69 (14.1)	2 (4.7)	33 (6.6)
	Any symptoms in prior 2 weeks	30 (29.4)	261 (26.4)	23 (39.0)	167 (34.5)	7 (16.3)	94 (18.7)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens. Pneumococcal detection was defined as  $C_T$  values below 40 for both the *lytA* and *piaB* targets.

Attribute <sup>1</sup>		Total	sample	n/N Clinic	(%) sample	Outreac	h sample
		Pneumococcus	Pneumococcus	Pneumococcus	Pneumococcus	Pneumococcus	Pneumococcus
		detected	not detected	detected	not detected	detected	not detected
		N=14	N=169	N=3	N=12	N=11	N=157
Age							
	18-29 years	4 (28.6)	66 (39.1)	1 (33.3)	7 (58.3)	3 (27.3)	59 (37.6)
	30-39 years	3 (21.4)	30 (17.8)	0 (0.0)	2 (16.7)	3 927.3)	28 (17.8)
	40-49 years	2 (14.3)	35 (20.7)	1 (33.3)	1 (8.3)	1 (9.1)	34 (21.7)
	≥50 years	5 (35.7)	38 (22.5)	1 (33.3)	2 (16.7)	4 (36.4)	36 (22.9)
Sex							
	Male	6 (42.9)	56 (33.1)	1 (33.3)	4 (33.3)	5 (45.5)	52 (33.1)
	Female	8 (57.1)	113 (66.9)	2 (66.7)	8 (66.7)	6 (54.5)	105 (66.9)
Language spoken at home							
	Spanish	8 (57.1)	112 (66.3)	2 (66.7)	7 (58.3)	6 (54.5)	105 (66.9)
	Indigenous language	0 (0.0)	1 (0.6)	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)
	English	6 (42.9)	56 (33.1)	1 (33.3)	4 (33.3)	5 (45.5)	52 (33.1)
Country of birth							
	Mexico	6 (42.9)	88 (52.1)	2 (66.7)	6 (50.0)	4 (36.4)	82 (52.2)
	United States	7 (50.0)	79 (46.7)	1 (33.3)	6 (50.0)	6 (54.5)	73 (46.5)
	Other	1 (7.1)	2 (1.2)	0 (0.0)	0 (0.0)	1 (9.1)	2 (1.3
Household crowding							
-	0-2 persons/bedroom	12 (85.7)	145 (85.8)	3 (100)	7 (58.3)	9 (81.8)	138 (87.9)
	2.1 to 4 persons/bedroom	2 (14.3)	22 (13.0)	0 (0.0)	5 (41.7)	2 (18.2)	17 (10.8)
	>4 persons/bedroom	0 (0.0)	2 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.3)
Exposure to children at home	•	· ,		. ,		. ,	. ,
	No children at home	3 (21.4)	57 (33.7)	1 (33.3)	5 (41.7)	2 (18.2)	52 (33.1)
	Any child <5 years old	4 (28.6)	49 (29.0)	0 (0.0)	6 (50.0)	4 (36.4)	43 (27.4)
	Children 5-18 years old only	7 (50.0)	63 (37.3)	2 (66.7)	21 (8.3)	5 (45.5)	62 (39.5)
Household income	, ,	· · ·	· · /	. ,	· · · ·	· · /	· · · ·
	<\$25,000	3 (25.0)	68 (43.6)	1 (50.0)	1 (9.1)	2 (20.0)	67 (46.2)
	\$25,000-34,999	3 (25.0)	24 (15.4)	0 (0.0)	4 (36.4)	3 (30.0)	20 (13.8)
	\$35,000-49,999	5 (41.7)	30 (19.2)	1 (50.0)	4 (36.4)	4 (40.0)	26 (17.9)
	≥\$50,000	1 (8.3)	34 (21.8)	0 (0.0)	2 (18.2)	1 (10.0)	32 (22.1)
Education level		· · · ·	· · · /	, , , , , , , , , , , , , , , , , , ,	· · · ·	. ,	· · · ·
	No formal schooling	0 (0.0)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)
	Primary school complete	3 (21.4)	35 (20.7)	1 (33.3)	3 (25.0)	2 (18.2)	32 (20.4)
	Junior high school complete	2 (14.3)	23 (13.6)	0 (0.0)	0 (0.0)	2 (18.2)	23 (14.6)
	High school complete	9 (64.3)	110 (65.1)	2 (66.7)	9 (75.Ó)	7 (63.6)	101 (64.3)
Housing type		、 ,	. ,	, , , , , , , , , , , , , , , , , , ,	· · /	. ,	. ,
5 77	Single-family house	4 (28.6)	73 (43.2)	3 (100.0)	6 (50.0)	1 (9.1)	67 (42.7)
	Apartment	10 (71.4)	91 (53.8)́	0 (0.0)	5 (41.7)	10 (90.9)	86 (54.8)
	Trailer/mobile home	0 (0.0)	2 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.3)
	Hotel/motel	0 (0.0)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)
	Other	0 (0.0)	2 (1.2)	0 (0.0)	1 (8.3)	0 (0.0)	1 (0.6)
Clinical status		. ,	. ,	. /	. /	, ,	· · /
	Current SARS-CoV-2 infection	5 (35.7)	10 (5.9)	1 (33.3)	0 (0.0)	4 (36.4)	10 (6.4)
	Any symptoms in prior 2 weeks	7 (50.0)	82 (48.5)	3 (100)	6 (50.0)	4 (36.4)	76 (48.4)

# Table S3: Characteristics of the pneumococcal sub-study population, by pneumococcal carriage status.

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens. Pneumococcal detection was defined as C<sub>T</sub> values below 40 for both the *lytA* and *piaB* targets.

<sup>1</sup>Abbreviated interviews with participants in the pneumococcal sub-study collected data on a reduced set of questions.

# Table S4: Association of SARS-CoV-2 infection with *lytA* detection in *piaB*-negative specimens.

Sample	Participants	SARS-CoV-2 infected/Total (%)				
-		lytA detected	lytA not detected	Unadjusted OR (95% CI)	Adjusted OR (95% CI) <sup>1</sup>	
Total sample						
	Primary study participants	28/193 (14.5)	74/793 (9.3)	1.63 (1.02, 2.61)	1.57 (0.96, 2.57)	
	Expanded dataset, including pneumococcal sub-study participants	29/218 (13.3)	83/937 (8.9)	1.55 (0.98, 2.44)		
Clinic-based sample						
	Primary study participants	23/99 (23.2)	46/387 (11.9)	2.24 (1.29, 3.91)	1.95 (1.07, 3.56)	
	Expanded dataset, including pneumococcal sub-study participants	23/100 (23.0)	46/398 (11.6)	2.28 (1.30, 3.98)		
Outreach-based sample		. ,	. ,	· · · · ·		
	Primary study participants	5/94 (5.3)	28/406 (6.9)	0.76 (0.29, 2.02)	0.77 (0.27, 2.18)	
	Expanded dataset, including pneumococcal sub-study participants	6/118 (5.1)	37/539 (6.9)	0.73 (0.30, 1.76)	/	

SARS nCoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Data are subset to specimens without *piaB* detection. We indicate dashes where models lacked sufficient sample to converge for all parameter estimates. <sup>1</sup>Adjusted odds ratios were not computed for analyses within the expanded dataset, as data were collected for a limited set of covariates among pneumococcal sub-study participants.

# Table S5: Unadjusted associations of SARS-CoV-2 infection with pneumococcal carriage detection within the expanded study population, including participants in the primary study and pneumococcal sub-study.

Participants	All testing venues	Clinic-based testing	Outreach-based testing	
	Unadjusted OR (95% CI)	Unadjusted OR (95% CI)	Unadjusted OR (95% CI)	
Total sample	3.31 (2.08, 5.24)	4.40 (2.50, 7.72)	1.80 (0.73, 4.45)	
Any symptoms in prior two weeks	4.15 (2.04, 8.42)	4.40 (1.87, 10.3)	3.64 (0.99, 13.4)	
No symptoms in prior two weeks	3.01 (1.50, 6.01)	4.73 (2.04, 10.9)	1.16 (0.26, 5.13)	

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Pneumococcal detection was defined as C<sub>7</sub> values below 40 for both the *lytA* and *piaB* targets.

Symptom	Symptom	Association with pneumococcal detection				Α	Association with SARS-CoV-2 detection			
	presence	Pneumococcus not detected	Pneumococcus detected	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	SARS-CoV-2 not detected	SARS-CoV-2 detected	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	
Dry cough	0	4 007	405			4 000	100			
	Symptom absent Symptom present	1,087 69	105 11	ref. 1.70 (0.83, 3.49)	ref. 1.44 (0.63, 3.29)	1,083 45	109 35	ref. 6.56 (3.81, 11.3)	ref. 7.10 (3.93, 12.9)	
Productive	Symptom present	09	11	1.70 (0.03, 3.49)	1.44 (0.03, 3.29)	40		0.50 (5.61, 11.5)	7.10 (3.93, 12.9)	
cough										
5	Symptom absent	1,095	106	ref.	ref.	1,082	119	ref.	ref.	
	Symptom present	61	10	1.25 (0.57, 2.74)	1.01 (0.41, 2.44)	46	25	3.85 (2.20, 6.74)	4.34 (2.36, 7.99)	
Pressure in ears							100			
	Symptom absent	1,136	109	ref.	ref.	1,112	133	ref.	ref.	
Blocked nose	Symptom present	20	7	3.13 (1.19, 8.27)	2.64 (0.85, 8.27)	16	11	3.87 (1.60, 9.33)	2.82 (1.03, 7.61)	
biocked hose	Symptom absent	1,087	108	ref.	ref.	1,077	118	ref.	ref.	
	Symptom present	69	8	0.97 (0.40, 2.35)	0.56 (0.20, 1.54)	51	26	3.32 (1.85, 5.97)	3.61 (1.90, 6.80)	
Runny nose	-,			,					,	
	Symptom absent	1,071	104	ref.	ref.	1,056	119	ref.	ref.	
	Symptom present	85	12	1.10 (0.51, 2.41)	0.97 (0.41, 2.27)	72	25	2.85 (1.63, 4.96)	3.35 (1.86, 6.04)	
Sneezing	<b>.</b>	1 000	405			4 000	110	,		
	Symptom absent	1,036 120	105	ref.	ref.	1,023 105	118 26	ref.	ref.	
Natery eyes	Symptom present	120	11	0.63 (0.26, 1.49)	0.64 (0.25, 1.58)	105	20	1.77 (1.00, 3.11)	2.04 (1.13, 3.72)	
valory cycs	Symptom absent	1,084	111	ref.	ref.	1,069	126	ref.	ref.	
	Symptom present	72	5	0.47 (0.14, 1.56)	0.40 (0.11, 1.39)	59	18	1.79 (0.92, 3.47)	1.80 (0.87, 3.70)	
loarse voice	, i i				( , , ,				( , , ,	
	Symptom absent	1,109	109	ref.	ref.	1,094	124	ref.	ref.	
_	Symptom present	47	7	1.02 (0.39, 2.69)	0.82 (0.29, 2.32)	34	20	3.18 (1.66, 6.08)	3.43 (1.70, 6.95)	
ever	0	1 100	100			4 4 6 4	110			
	Symptom absent	1,109 47	102 14	ref.	ref.	1,101 27	110 34	ref.	ref.	
Sweating	Symptom present	47	14	2.51 (1.23, 5.15)	1.79 (0.77, 4.24)	21	54	9.33 (5.13, 16.9)	10.3 (5.29, 20.1)	
Sweating	Symptom absent	1,110	106	ref.	ref.	1,096	120	ref.	ref.	
	Symptom present	46	10	1.91 (0.85, 4.31)	1.52 (0.60, 3.94)	32	24	5.13 (2.73, 9.68)	4.41 (2.17, 9.07)	
Chills					( · · · )				,	
	Symptom absent	1,083	102	ref.	ref.	1,078	107	ref.	ref.	
	Symptom present	73	14	1.99 (1.01, 3.92)	1.55 (0.71, 3.39)	50	37	5.90 (3.46, 10.0)	6.16 (3.45, 10.9)	
Headache	Cumptom aboost	997	04	rof	rof	000	92	rof	rof	
	Symptom absent Symptom present	159	94 22	ref. 1.44 (0.83, 2.50)	ref. 1.06 (0.57, 1.97)	999 129	92 52	ref. 3.63 (2.36, 5.60)	ref. 3.53 (2.24, 5.59)	
Tickle in throat	Oymptom present	100	22	1.44 (0.00, 2.00)	1.00 (0.07, 1.07)	120	52	5.05 (2.50, 5.00)	0.00 (2.24, 0.00)	
	Symptom absent	1,101	111	ref.	ref.	1,083	129	ref.	ref.	
	Symptom present	55	5	0.93 (0.32, 2.67)	1.00 (0.31, 3.07)	45	15	2.48 (1.22, 5.01	2.47 (1.14, 5.32)	
Sore throat										
	Symptom absent	1,044	103	ref.	ref.	1,038	109	ref.	ref.	
4 .1.1.	Symptom present	112	13	0.86 (0.41, 1.79)	0.72 (0.32, 1.60)	90	35	2.76 (1.68, 4.52)	2.96 (1.73, 5.09)	
Ayalgia	Symptom absent	1,060	103	ref.	rof	1 066	97	ref.	ref.	
	Symptom present	96	13	1.11 (0.55, 2.26)	ref. 0.62 (0.27, 1.44)	1,066 62	97 47	6.09 (3.76, 9.85)	7.08 (4.17, 12.0)	
Chest pain	cymptom prosont	50	10	(0.00, 2.20)	5.52 (5.27, 1.74)	<b>U</b> L	-11	5.00 (0.70, 5.00)	1.00 (4.17, 12.0)	
	Symptom absent	1,130	111	ref.	ref.	1,109	132	ref.	ref.	
	Symptom present	26	5	1.16 (0.34, 4.03)	0.60 (0.15, 2.41)	19	12	4.00 (1.73, 9.27)	3.55 (1.44, 8.81)	
Sinus pressure					. , ,			. ,	. ,	
	Symptom absent	1,135	112	ref.	ref.	1,112	135	ref.	ref.	

# Table S6: Association of clinical symptoms with pneumococcal carriage detection and SARS-CoV-2 infection.

Qualler slands	Symptom present	21	4	2.10 (0.58, 1.73)	1.93 (0.40, 8.75)	16	9	3.38 (1.19, 9.69)	2.83 (0.84, 9.78)
Swollen glands	Symptom absent	1,137	111	ref.	ref.	1,112	136	ref.	ref.
	Symptom present	19	5	1.36 (0.29, 5.85)	0.96 (0.16, 5.20)	16	8	2.12 (0.66, 6.78)	1.63 (0.40, 6.46)
Loss of appetite									. ,
	Symptom absent	1,116	111	ref.	ref.	1,105	122	ref.	ref.
Difficulty	Symptom present	40	5	1.42 (0.53, 3.78	1.11 (0.36, 3.40)	23	22	7.86 (3.94, 15.7)	9.57 (4.36, 20.8)
breathing									
5	Symptom absent	1,124	106	ref.	ref.	1,107	123	ref.	ref.
	Symptom present	32	10	3.04 (1.32, 7.03)	1.79 (0.65, 4.82)	21	21	8.13 (3.94, 16.8)	7.22 (3.29, 15.8)
Wheeze	Oursetens about	4 4 4 4	110	f		4 4 4 7	407	f	
	Symptom absent Symptom present	1,141 15	113 3	ref. 1.44 (0.31, 6.68)	ref. 1.08 (0.18, 6.47)	1,117 11	137 7	ref. 3.30 (1.06, 10.3)	ref. 3.41 (0.97, 12.1)
Shortness of	Symptom present	15	5	1.44 (0.51, 0.00)	1.00 (0.10, 0.47)		,	5.50 (1.00, 10.5)	5.41 (0.57, 12.1)
breath									
	Symptom absent	1,137	109	ref.	ref.	1,121	125	ref.	ref.
Diambas	Symptom present	19	7	3.61 (1.35, 9.73)	1.65 (0.45, 6.09)	7	19	28.9 (9.37, 88.5)	27.9 (8.29, 95.7)
Diarrhea	Symptom absent	1,115	113	ref.	ref.	1,100	128	ref.	ref.
	Symptom present	41	3	0.68 (0.20, 2.30)	0.46 (0.12, 1.76)	28	16	3.75 (1.89, 7.44)	4.97 (2.31, 10.6)
Nausea	- )								
	Symptom absent	1,113	109	ref.	ref.	1,093	129	ref.	ref.
0	Symptom present	43	7	1.42 (0.53, 3.73)	1.36 (0.47, 3.88)	35	15	2.73 (1.32, 5.63)	2.54 (1.15, 5.60)
Stomach pain	Symptom absent	1,106	112	ref.	ref.	1,092	126	ref.	ref.
	Symptom present	50	4	0.59 (0.18, 1.99	0.47 (0.13, 1.71)	36	18	3.20 (1.65, 6.20)	3.69 (1.79, 7.52)
Difficulty thinking	- )			,					
	Symptom absent	1,135	113	ref.	ref.	1,111	137	ref.	ref.
Fations	Symptom present	21	3	0.54 (0.07, 4.19)	0.27 (0.02, 3.09)	17	7	2.80 (0.95, 8.19)	2.43 (0.69, 8.56)
Fatigue	Symptom absent	1,062	102	ref.	ref.	1,052	112	ref.	ref.
	Symptom present	94	14	1.49 (0.77, 2.88)	1.16 (0.55, 2.42)	76	32	3.66 (2.21, 6.03)	3.80 (2.21, 6.51)
Loss of taste	- <b>)</b> Fre Free (								
	Symptom absent	1,122	112	ref.	ref.	1,115	119	ref.	ref.
Loop of small	Symptom present	34	4	0.94 (0.27, 3.16)	0.69 (0.15, 3.16)	13	25	12.9 (5.94, 28.0)	16.1 (6.67, 38.9)
Loss of smell	Symptom absent	1,127	112	ref.	ref.	1,118	121	ref.	ref.
	Symptom present	29	4	1.01 (0.30, 3.45)	0.71 (0.15, 3.50)	10	23	16.5 (7.18, 37.8)	18.1 (7.07, 46.5)
Pain in eyes					()				( , , , , , , , , , , , , , , , , , , ,
	Symptom absent	1,131	112	ref.	ref.	1,107	136	ref.	ref.
	Symptom present	25	4	1.23 (0.36, 4.26)	0.76 (0.18, 3.27)	21	8	2.11 (0.81, 5.50)	1.36 (0.45, 4.19)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Pneumococcal detection was defined as  $C_T$  values below 40 for both the *lytA* and *piaB* targets. Counts include participants in the primary and expanded study populations; unadjusted and adjusted odds ratios are computed using data from the primary study population only.

# Table S7: Association of clinical symptoms with detection of pneumococcus, stratifying by SARS-CoV-2 infection status.

Dry cough         Not detected         (98)           Dry cough         Not detected         Symptom absent         1.003         80           Detected         Symptom present         41         4         1.47 (0           Productive         Symptom absent         84         25         0.83 (0           Cough         Not detected         Symptom absent         1.001         81         Symptom absent         43         3         0.89 (0           Productive         Optected         Symptom absent         1.001         81         Symptom absent         1.031         81         Symptom absent         1.031         81         Symptom absent         0.91 (0         1.42 (0         1.43 (0         1.42 (0 </th <th colspan="6">Total sample</th>	Total sample					
Dry cough         Not detected         Symptom absent         1,003         80           Detected         Symptom present         41         4         1,47 (0           Productive cough         Symptom absent         1,001         81         25           Productive cough         Not detected         Symptom absent         1,001         81         3           Pressure in ears         Not detected         Symptom absent         18         7         0,91 (0           Pressure in ears         Not detected         Symptom present         13         3         3,14 (0           Blocked nose         Not detected         Symptom present         7         4         1,42 (0           Blocked nose         Not detected         Symptom present         96         81         0.97 (0           Runny nose         Not detected         Symptom present         91         27         0.52 (0           Runny nose         Not detected         Symptom present         92         27         0.58 (0           Seczing         Not detected         Symptom present         91         27         0.58 (0           Seczing         Not detected         Symptom present         92         27         0.58 (0	ljusted OR 95% CI)	Adjusted OR (95% CI)				
		(00,000)				
Productive Symptom absent Symptom present 28 7 0.83 (Constraints of the symptom present 28 7 0.91 (Constraints of the symptom present 29 7 0.91 (Constraints of the symptom present 20 7 0.92 (Constraints of the symptom present 20 7 0.92 (Constraints of the symptom present 20 7 0.92 (Constraints of the symptom present 20 7 0.93 (Constraints of the symptom present 20 7 0.93 (Constraints of the symptom present 10.11 4 0.48 (Constraints of the symptom present 10.11 4 0.48 (Constraints of the symptom present 10.93 (Constr	ref.	ref.				
Productive soughSymptom besent Symptom present84 2825 70.83 (f 0.83 (f 0.89 (f 0.81 (f 0.81 (f 0.81 (f 0.81 (f 0.81 (f 0.81 (f 	0.50, 4.51)	1.98 (0.63, 6.18				
Symptom present2870.83 (CProductive coughNot detectedSymptom absent1,0018130.89 (CSymptom present4330.89 (C30.89 (CSymptom bresent14330.89 (C30.89 (CPressure in earsNot detectedSymptom present1870.91 (CSymptom present1.0318133.14 (CDetectedSymptom present1052828Symptom present741.42 (C1.42 (CBlocked noseSymptom present741.42 (CBlocked noseSymptom present91270.52 (CNot detectedSymptom present2150.52 (CSymptom present91270.52 (C27Runny noseNot detectedSymptom present6571.26 (CStreezingNot detectedSymptom present92270.58 (CNot detectedSymptom present93250.58 (CSymptom present10140.48 (C27Symptom present10140.48 (CSymptom present93250.58 (CSymptom present10140.46 (CSymptom present1012220.81 (CHoarse voiceNot detectedSymptom present322FeverNot detectedSymptom present3220.81 (CSymptom present1012	ref.	ref.				
Productive cough Not detected Symptom absent 1.001 81 3 0.89 (C Symptom present 43 3 0.89 (C Symptom present 13 0.81 0.81 0.81 0.81 0.81 0.81 0.81 0.81	(0.29, 2.38)	0.89 (0.21, 3.81				
Not detectedSymptom absent Symptom present1.00181 330.89 (CPressure in earsSymptom absent Symptom present94 1825 70.91 (CPressure in earsNot detectedSymptom absent Symptom present1.03181 33.14 (CDetectedSymptom absent Symptom present1.03181 33.14 (CBlocked noseNot detectedSymptom absent Symptom present99681 30.97 (CBlocked noseNot detectedSymptom absent Symptom present916 27 2127 50.52 (CRunny noseNot detectedSymptom absent Symptom present979 2177 50.52 (CRunny noseNot detectedSymptom absent Symptom present979 2177 50.52 (CStreezingNot detectedSymptom absent Symptom present979 27 27 2077 200.58 (CNot detectedSymptom absent Symptom present913 25 727 200.58 (CNot detectedSymptom absent Symptom present93 25 727 200.68 (CNot detectedSymptom absent Symptom present93 22 22 270.72 (CHoarse voiceNot detected Symptom present32 22 200.81 (CHoarse voiceNot detected Symptom present32 22 200.81 (CFeverNot detected Symptom present32 22 200.81 (CFeverNot detected Symptom present24 <b< td=""><td>, ,</td><td></td></b<>	, ,					
Symptom absent         1.001         81           Detected         Symptom present         43         3         0.69 (C           Pressure in ears         Symptom absent         94         25         0.91 (C           Not detected         Symptom absent         1.031         81         7         0.91 (C           Blocked nose         Not detected         Symptom absent         1.031         81         3         3.14 (C           Blocked nose         Not detected         Symptom present         7         4         1.42 (C           Blocked nose         Not detected         Symptom present         91         27         6         28           Runny nose         Not detected         Symptom present         91         27         5         0.52 (C           Runny nose         Not detected         Symptom present         979         77         1.26 (C         5         5         0.52 (C         27         5         0.58 (C         27         0.59 (C         27         0.27 (C         27						
Pressure in ears Symptom absent Pressure in ears Pressure in ears Not detected Not detected Symptom absent Detected Symptom absent Detected Symptom absent Symptom absent Symptom absent Symptom absent Detected Symptom absent Symptom absen	ref.	ref.				
Symptom absent 94 25 Symptom present 18 7 0.91 (C Not detected Symptom present 13 3 3.14 (C Symptom present 13 3 3.14 (C Symptom present 7 4 1.42 (C Not detected Symptom present 7 4 1.42 (C Not detected Symptom present 996 81 Symptom present 48 3 0.97 (C Symptom absent 997 77 Symptom present 21 5 0.52 (C Not detected Symptom absent 979 77 Detected Symptom present 20 5 0.58 (C Not detected Symptom present 91 4 0.48 (C Symptom present 20 5 0.58 (C Not detected Symptom present 943 80 Symptom present 101 4 0.48 (C Symptom present 93 25 Symptom present 101 4 0.48 (C Symptom present 943 80 Symptom present 101 4 0.48 (C Symptom present 101 4 0.48 (C Sym	0.26, 2.99)	1.05 (0.30, 3.68				
Symptom present 18 7 0.91 (C Pressure in ears Not detected Symptom absent 1,031 81 Detected Symptom present 13 3 3.14 (C Symptom present 13 3 3.14 (C Symptom present 7 4 1.42 (C Not detected Symptom absent 996 81 Detected Symptom present 21 5 0.52 (C Not detected Symptom absent 91 27 Symptom present 21 5 0.52 (C Not detected Symptom absent 92 27 Symptom present 65 7 1.26 (C Symptom present 20 5 0.58 (C Not detected Symptom absent 92 27 Symptom present 101 4 0.48 (C Symptom pre	ref.	ref.				
Pressure in ears Not detected Symptom absent Symptom present 1,031 81 3,14 (0 2,00 2,00 2,00 2,00 2,00 2,00 2,00 2,	(0.30, 2.82)	0.57 (0.11, 3.07				
	, -,					
$\begin{array}{c} \label{eq:baseline} \\ \begin{tabular}{ c c c } \hline \end{tabular} \\ \end{tilty} \\ $	ref.	ref.				
	(0.85, 11.7)	4.87 (1.07, 23.3				
Blocked nose Symptom present Not detected Not detected Symptom absent Symptom present 48 3 0.97 (C Symptom absent 996 81 3 0.97 (C Symptom absent 91 27 5 0.52 (C Symptom absent 979 77 1.26 (C Symptom absent 979 77 1.26 (C Symptom absent 97 7 1.26 (C Symptom absent 92 27 5 0.58 (C Symptom absent 92 27 5 0.58 (C Symptom absent 93 25 0.58 (C Symptom absent 93 25 0.72 (C Symptom absent 93 25 0.72 (C Symptom absent 93 25 0.72 (C Symptom absent 943 80 Symptom absent 93 25 0.72 (C Symptom absent 986 83 1 0.27 (C Symptom absent 98 28 1 0.27 (C Symptom absent 98 28 2 C C Symptom absent 98 28 2 C C Symptom absent 98 28 2 C C C C Symptom absent 98 28 28 2 C C C C C C C C C C C C C C C	ref.	ref.				
Slocked nose       Not detected       Symptom absent       996       81       0.97 (0         Burny nose       Symptom absent       91       27       0.52 (0         Runny nose       Not detected       Symptom absent       91       27         Not detected       Symptom present       21       5       0.52 (0         Not detected       Symptom present       65       7       1.26 (0         Detected       Symptom present       20       5       0.58 (0         Sneezing       Not detected       Symptom present       91       4       0.48 (0         Detected       Symptom present       93       25       0.58 (0       0.58 (0         Watery eyes       Not detected       Symptom present       93       25       0.58 (0         Watery eyes       Not detected       Symptom present       93       25       0.72 (0         Matery eyes       Not detected       Symptom present       986       83       0.27 (0         Oetected       Symptom present       1.012       82       0.81 (0         Oetected       Symptom absent       97       27       0.69 (0         Symptom present       1.012       82       0.81 (0       0.8	(0.33, 6.25)	0.33 (0.00, 11.6				
Not detectedSymptom absent Symptom present996 4881 30.97 (0 0.52 (0Runny noseNot detectedSymptom present91 27 5ymptom present27 210.52 (0Runny noseNot detectedSymptom present91 2127 50.52 (0Not detectedSymptom present92 527 0.58 (00.68 (0DetectedSymptom absent92 527 0.58 (00.58 (0SneezingNot detectedSymptom present10140.48 (0DetectedSymptom present10140.48 (0DetectedSymptom present93 Symptom present25 10.72 (0Natery eyesNot detectedSymptom absent986 3 110.27 (0Hoarse voiceNot detectedSymptom present1.012 3282 20.81 (0Hoarse voiceNot detectedSymptom present1.012 3282 20.81 (0Hoarse voiceNot detectedSymptom absent Symptom present97 3227 20.81 (0Hoarse voiceNot detectedSymptom absent Symptom present1.012 3282 20.81 (0Hoarse voiceNot detectedSymptom present1.020 3281 31.80 (0Hoarse voiceNot detectedSymptom present23 321.30 (0Hoarse voiceSymptom absent Symptom present89 3221 331.30 (0Hoarse voiceSymptom absent Symptom present24 <br< td=""><td>0.00, 0.20)</td><td>0.00 (0.00, 11.0</td></br<>	0.00, 0.20)	0.00 (0.00, 11.0				
$ \begin{tabular}{ c c c c } & & & & & & & & & & & & & & & & & & &$						
DetectedSymptom absent Symptom present91 2127 50.52 (d)Runny noseNot detectedSymptom present6571.26 (d)Not detectedSymptom bresent6571.26 (d)DetectedSymptom absent9227 50.58 (d)SneezingNot detectedSymptom absent94380 4DetectedSymptom absent94380 40.48 (d)DetectedSymptom absent9325 50.72 (d)Watery eyesNot detectedSymptom absent98683 4Not detectedSymptom bresent10140.46 (d)Hoarse voiceNot detectedSymptom present1440.46 (d)Hoarse voiceNot detectedSymptom present1,01282 40.81 (d)FeverNot detectedSymptom present1,01282 40.69 (d)FeverNot detectedSymptom present1,02081 41.80 (d)SweatingNot detectedSymptom present2431.80 (d)SweatingNot detectedSymptom absent89 421 41.33 (d)SweatingNot detectedSymptom absent1,01581	ref.	ref.				
Symptom absent Symptom present91 2127 50.52 (0Runny noseNot detectedSymptom present6571.26 (0DetectedSymptom present6571.26 (0Some absent9227 Symptom present2050.58 (0SneezingNot detectedSymptom absent94380 Symptom present80 Symptom present9325 Not detectedWatery eyesNot detectedSymptom absent9325 Symptom present9325 Not detected70.72 (0Watery eyesNot detectedSymptom absent98683 Not 220.81 (0Hoarse voiceSymptom absent9828 Symptom present200.69 (0Hoarse voiceNot detectedSymptom absent97 Symptom present27 Not detectedFeverNot detectedSymptom absent97 Symptom present27 Not detectedFeverNot detectedSymptom absent97 Symptom present27 Not 26SweatingNot detectedSymptom absent24 Simptom present3SweatingNot detectedSymptom present24 Simptom present3SweatingNot detectedSymptom present24 Simptom present3SweatingNot detectedSymptom present24 Simptom present3SweatingNot detectedSymptom present24 Simptom present3Symptom absentSimptom present24 Simptom present<	(0.29, 3.28)	0.98 (0.27, 3.54				
Runny noseSymptom present2150.52 (CNot detectedSymptom absent9797777DetectedSymptom present6571.26 (CSneezingNot detectedSymptom absent9227Not detectedSymptom absent9227Supptom absent92270.58 (CDetectedSymptom absent94380DetectedSymptom present1014ObjectedSymptom present1014Watery eyesNot detectedSymptom present93Not detectedSymptom absent98683Symptom present5810.27 (CHoarse voiceSymptom absent98683Hoarse voiceSymptom absent98682Not detectedSymptom absent1,01282Symptom present1440.46 (CSymptom present3220.81 (CSymptom present1,012820.69 (CFeverNot detectedSymptom present2431.80 (CSymptom absent9.7270.72 (C0.69 (CFeverNot detectedSymptom present2431.80 (CSymptom absent9.92131.33 (CSweatingNot detectedSymptom present23111.33 (CSweatingNot detectedSymptom absent89213Symptom absent1,015813		_				
Runny noseNot detectedSymptom absent97977Symptom present6571.26 (0DetectedSymptom absent9227Symptom present2050.58 (0DetectedSymptom absent94380DetectedSymptom absent94380DetectedSymptom absent9325Symptom absent93250.72 (0Watery eyesNot detectedSymptom absent98683DetectedSymptom absent986830.27 (0DetectedSymptom present1440.46 (0Hoarse voiceNot detectedSymptom present220.81 (0Hoarse voiceNot detectedSymptom absent9727FeverNot detectedSymptom present1,01282Symptom present1550.69 (0FeverNot detectedSymptom present23111.33 (0Symptom absent23111.33 (01.33 (0SweatingNot detectedSymptom absent8921Symptom absent23111.33 (0SweatingNot detectedSymptom absent1,01581	ref.	ref.				
Not detected Symptom absent 979 77 Symptom present 65 7 1.26 (0 Symptom absent 92 27 Symptom present 20 5 0.58 (0 Not detected Symptom absent 943 80 Detected Symptom present 101 4 0.48 (0 Symptom absent 93 25 Symptom absent 93 25 Symptom present 10 7 0.72 (0 Natery eyes Not detected Symptom absent 986 83 Detected Symptom absent 986 83 Detected Symptom absent 988 28 Symptom present 14 4 0.46 (0 Symptom absent 98 28 Symptom present 15 1 0.27 (0 Symptom absent 98 28 Symptom absent 98 28 Symptom present 12 2 0.81 (0 Detected Symptom absent 98 28 Symptom present 15 5 0.69 (0 Symptom absent 97 27 Symptom present 15 5 0.69 (0 Symptom absent 97 27 Symptom present 15 5 0.69 (0 Symptom absent 97 27 Symptom present 24 3 1.80 (0 Symptom absent 24 3 1.80 (0 Symptom absent 24 3 1.80 (0 Symptom absent 23 11 1.33 (0 Sweating Not detected Symptom absent 1.015 81	0.14, 1.97)	0.14 (0.02, 1.21				
$ \begin{array}{c} eq:spectral symptom absent symptom present symptom present symptom present symptom present 20 5 0.58 (Constraints of the symptom absent symptom present 20 5 0.58 (Constraints of the symptom absent 20 5 0.58 (Constraints of the symp$						
$\operatorname{Petected}$ $\operatorname{Symptom present}$ $\operatorname{Symptom absent}$ $\operatorname{Symptom absent}$ $\operatorname{Symptom absent}$ $\operatorname{Symptom absent}$ $\operatorname{Petected}$ $\operatorname{Petected}$ $\operatorname{Symptom absent}$ $\operatorname{Petected}$ $Petec$	ref.	ref.				
$\begin{tabular}{ c c c c } \hline Detected & & & & & & & & & & & & & & & & & & &$	(0.48, 3.34)	1.31 (0.47, 3.66				
Symptom present         20         5         0.58 (0)           Sneezing         Not detected         Symptom absent         943         80           Detected         Symptom absent         943         80         30           Watery eyes         Detected         Symptom present         101         4         0.48 (0)           Watery eyes         Not detected         Symptom absent         93         25         70.72 (0)           Watery eyes         Not detected         Symptom present         19         7         0.72 (0)           Watery eyes         Not detected         Symptom absent         986         83         0.27 (0)           Watery eyes         Not detected         Symptom absent         986         28         0.27 (0)           Hoarse voice         Symptom absent         98         28         0.27 (0)         0.27 (0)           Hoarse voice         Not detected         Symptom present         14         4         0.46 (0)           Fever         Not detected         Symptom present         32         2         0.81 (0)           Symptom absent         97         27         0.69 (0)         0         0           Fever         Not detected         Symptom pres						
SheezingNot detectedSymptom absent $943$ $80$ 4DetectedSymptom present $101$ $4$ $0.48$ (0Watery eyesSymptom absent $93$ $25$ Symptom present $19$ $7$ $0.72$ (0Watery eyesNot detectedSymptom absent $986$ $83$ 1 $0.27$ (0DetectedSymptom absent $986$ $83$ 1 $0.27$ (0Hoarse voiceSymptom absent $98$ $28$ Symptom present $14$ $4$ $0.46$ (0Hoarse voiceNot detectedSymptom absent $98$ $28$ Symptom present $22$ $14$ $0.81$ (0FeverNot detectedSymptom absent $97$ Symptom present $27$ $5$ $0.69$ (0FeverNot detectedSymptom absent $97$ Symptom present $27$ $5$ $0.69$ (0FeverNot detectedSymptom absent $1,012$ Symptom present $81$ $23$ $1.80$ (0SweatingNot detectedSymptom absent $89$ Symptom present $23$ $23$ $11$ $1.33$ (0	ref.	ref.				
Not detectedSymptom absent94380DetectedSymptom present10140.48 (0Watery eyesSymptom absent9325Not detectedSymptom present1970.72 (0DetectedSymptom absent986830.27 (0DetectedSymptom absent986830.27 (0Hoarse voiceSymptom absent986830.27 (0Hoarse voiceSymptom absent986280.46 (0Hoarse voiceSymptom absent98280.46 (0Hoarse voiceSymptom present1,012820.81 (0Hoarse voiceSymptom absent1,012820.81 (0Hoarse voiceSymptom absent1,0208131.80 (0FeverNot detectedSymptom present2431.80 (0Symptom absent23111.33 (033SweatingNot detectedSymptom absent8921SweatingNot detectedSymptom absent1,01581	(0.15, 2.23)	0.36 (0.05, 2.30				
$ \begin{array}{c} \begin{array}{c} & \\ \text{Detected} \\ \\ \text{Detected} \\ \end{array} \\ \begin{array}{c} \text{Detected} \\ \text{Symptom present} \\ \text{Symptom present} \\ 101 \\ 4 \\ 0.48 (0) \\ 4 \\ 0.48 (0) \\ 4 \\ 0.48 (0) \\ 101 \\ 4 \\ 0.48 (0) \\ 101 \\ 101 \\ 4 \\ 0.48 (0) \\ 101 \\$						
Symptom present10140.48 (0DetectedSymptom absent9325Symptom present1970.72 (0Watery eyesNot detectedSymptom absent98683DetectedSymptom absent98683DetectedSymptom absent98828Symptom absent98280.27 (0Hoarse voiceSymptom absent9828Not detectedSymptom present144Hoarse voiceSymptom absent1,01282Symptom absent1,012820.81 (0FeverSymptom absent9727Symptom absent1,02081Symptom absent2431.80 (0SweatingSymptom absent8921SweatingNot detectedSymptom present23111.33 (0SweatingNot detectedSymptom absent1,015811	ref.	ref.				
DetectedSymptom absent Symptom present93 1925 7Watery eyesNot detected1970.72 (0Not detectedSymptom absent Symptom present986 5883 10.27 (0Hoarse voiceSymptom absent Symptom present98 1428 40.46 (0Hoarse voiceNot detectedSymptom absent Symptom present98 1428 40.46 (0Hoarse voiceNot detectedSymptom absent Symptom present1,012 3282 20.81 (0FeverNot detectedSymptom absent Symptom present1,012 15815FeverNot detectedSymptom absent Symptom present1,020 2481 31.80 (0SweatingNot detectedSymptom absent Symptom present2311 231.33 (0SweatingNot detectedSymptom absent Symptom present89 21 2311 231.33 (0	(0.15, 1.60)	0.54 (0.16, 1.83				
Watery eyes           Watery eyes         Not detected         Symptom present         19         7         0.72 (0           Not detected         Symptom absent         986         83         1         0.27 (0           Detected         Symptom present         58         1         0.27 (0           Hoarse voice         Symptom absent         986         83         1         0.27 (0           Hoarse voice         Symptom absent         98         28         14         4         0.46 (0           Hoarse voice         Not detected         Symptom present         14         4         0.46 (0           Hoarse voice         Not detected         Symptom present         32         2         0.81 (0           Petected         Symptom absent         97         27         0.69 (0         5         0.69 (0           Fever         Not detected         Symptom absent         1,020         81         3         1.80 (0           Sweating         Detected         Symptom present         23         11         1.33 (0           Sweating         Not detected         Symptom absent         1,015         81         5	,0110, 1100)					
Watery eyes Not detected Symptom absent Symptom present Symptom present Symptom present Symptom present Symptom present Symptom present Symptom absent Symptom absent Symptom absent Symptom present Symptom absent Symptom absent Symptom present Symptom present Symptom absent Sy	ref.	ref.				
Not detectedSymptom absent Symptom present986 5883 10.27 (0 0.27 (0 0.28)Hoarse voiceSymptom absent Symptom present98 1428 40.46 (0 0.46 (0Hoarse voiceNot detectedSymptom present1440.46 (0 0.46 (0Hoarse voiceNot detectedSymptom absent Symptom present1,012 3282 20.81 (0 0.69 (0FeverNot detectedSymptom absent Symptom present97 1527 50.69 (0FeverNot detectedSymptom absent Symptom present1,020 2481 31.80 (0SweatingNot detectedSymptom absent Symptom present23 21 2311 1.33 (0SweatingNot detectedSymptom absent Symptom absent1,015 2381 21	(0.19, 2.81)	1.80 (0.25, 13.2				
DetectedSymptom absent Symptom present98683 10.27 (0) 0.27 (0)Hoarse voiceSymptom absent Symptom present9828 28 40.46 (0)Hoarse voiceNot detectedSymptom absent Symptom present1,012 3282 20.81 (0)FeverSymptom absent Symptom present97 1527 50.69 (0)FeverNot detectedSymptom absent Symptom present1,020 1581SweatingNot detectedSymptom absent Symptom present23 21 2311 1 1.33 (0)SweatingNot detectedSymptom absent Symptom absent89 23 21 2321 1 1.33 (0)						
DetectedSymptom present5810.27 (0)Hoarse voiceSymptom absent9828Not detectedSymptom present1440.46 (0)Not detectedSymptom absent1,01282DetectedSymptom present3220.81 (0)FeverSymptom absent9727Not detectedSymptom present1550.69 (0)FeverNot detectedSymptom absent1,02081DetectedSymptom absent2431.80 (0)SweatingNot detectedSymptom present23111.33 (0)SweatingNot detectedSymptom absent8921SweatingNot detectedSymptom absent1,01581	rof					
DetectedSymptom absent Symptom present98 1428 40.46 (0Hoarse voiceNot detected1,012 Symptom present82 3220.81 (0Not detectedSymptom absent Symptom present97 3227 50.69 (0FeverNot detectedSymptom absent Symptom present97 1527 50.69 (0FeverNot detectedSymptom absent Symptom present1,020 2481 31.80 (0SweatingNot detectedSymptom absent Symptom present23 2311 11.33 (0SweatingNot detectedSymptom absent Symptom absent1,01581	ref. (0.04, 2.07)	ref. 0.25 (0.03, 2.02				
Hoarse voice Hoarse voice Not detected Symptom absent Symptom abse	0.04, 2.07)	0.23 (0.03, 2.02)				
Hoarse voice Not detected Symptom absent 1,012 82 Detected Symptom absent 32 2 0.81 (0 Symptom absent 97 27 Symptom present 15 5 0.69 (0 Pever Not detected Symptom absent 1,020 81 Symptom absent 24 3 1.80 (0 Detected Symptom absent 89 21 Symptom present 23 11 1.33 (0 Sweating Not detected Symptom absent 1,015 81	ref.	ref.				
Hoarse voice Not detected Symptom absent 1,012 82 Symptom present 32 2 0.81 (0 Detected Symptom absent 97 27 Symptom present 15 5 0.69 (0 Fever Not detected Symptom absent 1,020 81 Symptom present 24 3 1.80 (0 Detected Symptom absent 89 21 Symptom present 23 11 1.33 (0 Sweating Not detected Symptom absent 1,015 81	(0.09, 2.28)					
Symptom absent1,01282Symptom present3220.81 (0Symptom absent9727Symptom present1550.69 (0FeverNot detected50.69 (0Not detectedSymptom absent1,02081Symptom present2431.80 (0DetectedSymptom absent8921SweatingSymptom absent23111.33 (0Not detectedSymptom absent1,01581	,					
Symptom present3220.81 (0DetectedSymptom absent9727Symptom present1550.69 (0FeverNot detectedSymptom absent1,02081DetectedSymptom present2431.80 (0DetectedSymptom absent8921SweatingNot detected23111.33 (0Not detectedSymptom absent1,01581						
Detected       Symptom absent       97       27         Symptom present       15       5       0.69 (0         Fever       Not detected       Symptom absent       1,020       81         Detected       Symptom present       24       3       1.80 (0         Detected       Symptom absent       89       21         Sweating       Symptom present       23       11       1.33 (0         Sweating       Not detected       Symptom absent       1,015       81	ref.	ref.				
Fever Symptom absent 97 27 Symptom present 15 5 0.69 (0 Not detected Symptom absent 1,020 81 Symptom present 24 3 1.80 (0 Detected Symptom absent 89 21 Symptom present 23 11 1.33 (0 Sweating Not detected Symptom absent 1,015 81	(0.19, 3.59)	0.80 (0.17, 3.70				
Symptom present       15       5       0.69 (0         Fever       Not detected       Symptom absent       1,020       81         Symptom present       24       3       1.80 (0         Detected       Symptom absent       89       21         Symptom present       23       11       1.33 (0         Sweating       Not detected       Symptom absent       1,015       81	ref.	ref.				
Fever Not detected Symptom absent Symptom present 24 3 1.80 (0 Detected Symptom absent 89 21 Symptom present 23 11 1.33 (0 Not detected Symptom absent 1,015 81	(0.18, 2.72)	0.66 (0.07, 5.94				
Not detected Symptom absent 1,020 81 Symptom present 24 3 1.80 (0 Detected Symptom absent 89 21 Symptom present 23 11 1.33 (0 Sweating Not detected Symptom absent 1,015 81	, <b></b> /	0.00 (0.07, 0.04				
Symptom present 24 3 1.80 (C Detected Symptom absent 89 21 Symptom present 23 11 1.33 (C Not detected Symptom absent 1,015 81						
Detected Symptom absent 89 21 Symptom present 23 11 1.33 (0 Not detected Symptom absent 1,015 81	ref.	ref.				
Symptom absent 89 21 Symptom present 23 11 1.33 (C Not detected Symptom absent 1,015 81	(0.52, 6.36)	2.28 (0.59, 8.94				
Sweating Not detected Symptom present 23 11 1.33 (C Not detected Symptom absent 1,015 81						
Sweating Not detected Symptom absent 1,015 81	ref.	ref.				
Not detected Symptom absent 1,015 81	(0.50, 3.56)	1.69 (0.46, 6.11				
Symptom absent 1,015 81						
	ref.	ref.				
	(0.46, 5.54)	2.00 (0.52, 7.73				
Detected						
Symptom absent 95 25	ref.	ref.				

Chills		Symptom present	17	7	1.03 (0.33, 3.25)	1.11 (0.21, 5.89)
	Not detected	Symptom absent Symptom present	998 46	80 4	ref. 1.49 (0.50, 4.35)	ref. 1.76 (0.56, 5.48)
	Detected	Symptom absent Symptom present	85 27	22 10	ref. 1.04 (0.39, 2.78)	ref. 1.20 (0.34, 4.22)
Headache	Not detected	Symptom absent	924	75	ref.	ref.
	Detected	Symptom present Symptom absent Symptom present	120 73 39	9 19 13	1.26 (0.60, 2.61) ref. 0.86 (0.34, 2.18)	1.25 (0.58, 2.67) ref. 0.56 (0.16, 1.89)
Tickle in throat	Not detected	Symptom absent	1,002	81	ref.	ref.
	Detected	Symptom absent	42	3	1.30 (0.38, 4.38) ref.	1.95 (0.53, 6.87) ref.
Sore throat	Not detected	Symptom present	13	2	0.27 (0.03, 2.27)	0.35 (0.03, 4.17)
	Detected	Symptom absent Symptom present	958 86	80 4	ref. 0.49 (0.15, 1.62)	ref. 0.58 (0.17, 1.93)
Myalgia		Symptom absent Symptom present	86 26	23 9	ref. 0.80 (0.28, 2.29)	ref. 0.72 (0.18, 2.84)
	Not detected	Symptom absent Symptom present	984 60	82 2	ref. 0.50 (0.12, 2.08)	ref. 0.52 (0.11, 2.23)
Chest pain	Deletica	Symptom absent Symptom present	76 36	21 11	ref. 0.70 (0.27, 1.85)	ref. 0.43 (0.11, 1.66)
	Not detected	Symptom absent Symptom present	1,026 18	83 1	ref. 0.81 (0.10, 6.45)	ref. 0.56 (0.06, 5.08)
	Detected	Symptom absent Symptom present	104 8	28 4	ref. 0.75 (0.15, 3.88)	ref. 0.95 (0.10, 9.55)
Sinus pressure	Not detected	Symptom absent Symptom present	1,029 15	83 1	ref. 1.49 (0.18, 10.8)	ref. 3.42 (0.38, 29.7)
	Detected	Symptom absent Symptom present	106 6	29 3	ref. 1.41 (0.24, 8.30)	
Swollen glands	Not detected	Symptom absent	1,029 15	83	ref. 1.14 (0.14, 8.05)	ref. 2.20 (0.22, 19.2)
	Detected	Symptom present Symptom absent Symptom present	108 4	1 28 4	ref. 0.92 (0.09, 9.41)	
Loss of appetite	Not detected	Symptom absent	1,023	82	ref.	ref.
	Detected	Symptom present	21 93	2 29	1.76 (0.38, 7.79) ref.	2.44 (0.45, 12.8) ref.
Difficulty breathing	Not detected	Symptom present	19	3	0.52 (0.14, 1.97)	0.55 (0.12, 2.58)
	Detected	Symptom absent Symptom present	1,026 18	81 3	ref. 3.18 (0.86, 11.5)	ref. 4.07 (0.96, 16.9)
Wheeze		Symptom absent Symptom present	98 14	25 7	ref. 1.25 (0.39, 4.00)	ref. 0.95 (0.17, 5.30)
	Not detected	Symptom absent Symptom present	1,033 11	84 0		
	Detected					

Shortness of		Symptom absent Symptom present	108 4	29 3	ref. 1.90 (0.30, 12.2)	
breath	Not detected					
	Detected	Symptom absent Symptom present	1,037 7	84 0		
Diarrhea	Deletica	Symptom absent Symptom present	100 12	25 7	ref. 1.94 (0.63, 6.04)	ref. 2.39 (0.50, 11.7)
Diattiea	Not detected					
	Detected	Symptom absent Symptom present	1,016 28	84 0		
Naussa	2000000	Symptom absent Symptom present	99 13	29 3	ref. 0.71 (0.18, 2.79)	ref. 1.16 (0.12, 11.7)
Nausea	Not detected					
	Detected	Symptom absent Symptom present	1,011 33	82 2	ref. 1.17 (0.26, 4.69)	ref. 1.26 (0.27, 5.56)
	Deletitu	Symptom absent Symptom present	102 10	27 5	ref. 0.91 (0.23, 3.71)	ref. 1.65 (0.25, 11.1)
Stomach pain	Not detected					
	Detected	Symptom absent Symptom present	1,009 35	83 1	ref. 0.37 (0.05, 2.85)	ref. 0.38 (0.05, 3.34)
	Delected	Symptom absent Symptom present	97 15	29 3	ref. 0.49 (0.10, 2.38)	ref. 0.63 (0.09, 4.73)
Difficulty thinking	Not detected					
		Symptom absent Symptom present	1,028 16	83 1	ref. 0.94 (0.12, 7.51)	ref. 0.91 (0.08, 10.5)
	Detected	Symptom absent Symptom present	107 5	30 2		
Fatigue	Not detected					
	Detected	Symptom absent Symptom present	972 72	80 4	ref. 0.89 (0.31, 2.52)	ref. 0.84 (0.28, 2.49)
	Delected	Symptom absent Symptom present	90 22	22 10	ref. 1.19 (0.45, 3.20)	ref. 1.20 (0.35, 4.18)
Loss of taste	Not detected					
		Symptom absent	1,031	84		
	Detected	Symptom present	13	0		
Loss of smell		Symptom absent Symptom present	91 21	28 4	ref. 0.55 (0.15, 2.12)	ref. 0.96 (0.13, 6.77)
LOSS OF SITIEI	Not detected					
		Symptom absent Symptom present	1,034 10	84 0		
	Detected					
		Symptom absent Symptom present	93 19	28 4	ref. 0.52 (0.14, 1.97)	ref. 0.74 (0.10, 5.29)
Pain in eyes	Natal de Contra 1	- , , ,		-	(,)	()
	Not detected	Symptom absent	1,023	84		
	Detected	Symptom present	21	0		
	Delected	Symptom absent Symptom present	108 4	28 4	ref. 2.95 (0.56, 15.9)	
SARS COV 2. Sovo	ro acuto rochirat	ory syndrome coronavir	botocto a contract	by clinical transcr	intion modiated ampli	fication testing from or

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Pneumococcal detection was defined as C<sub>T</sub> values below 40 for both the *lytA* and *piaB* targets. Counts include participants in the primary and expanded study populations; unadjusted and adjusted odds ratios are computed using data from the primary study population only. We indicate dashes where models lacked sufficient sample to converge for all parameter estimates.

#### Table S8: Association of SARS-CoV-2 infection with pneumococcal carriage at *lytA* C<sub>1</sub><35 and *piaB* C<sub>1</sub><35 detection thresholds.


Participants	Total s	ample	Clinic s	ample	Outreach sample		
	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	
Total sample	3.89 (2.03, 7.46)	4.53 (2.20, 9.41)	5.54 (2.61, 11.7)	6.70 (2.80, 15.9)	0.91 (0.12, 6.97)	1.88 (0.20, 17.4)	
Any symptoms in prior two weeks	4.07 (1.39, 12.1)	4.80 (1.36, 17.1)	4.42 (1.35, 15.4)	6.81 (1.39, 34.5)			
No symptoms in prior two weeks	4.09 (1.66, 9.94)	4.32 (1.55, 12.1)	7.56 (2.67, 21.4)	10.4 (2.80, 39.3)			

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Pneumococcal detection was defined as C<sub>T</sub> values below 35 for both the *lytA* and *piaB* targets. Data include participants enrolled in the primary study only. We indicate dashes where models lacked sufficient sample to converge for all parameter estimates.

# Table S9: Association of salivary SARS-CoV-2 C<sub>7</sub> values with pneumococcal carriage detection.

Population		Association with SAF	RS-CoV-2 N gene c⊤	Association with SAF	RS-CoV-2 E gene c⊤
		Unadjusted $\beta$ (95% CI)	Adjusted $\beta$ (95% CI)	Unadjusted $\beta$ (95% CI)	Adjusted $\beta$ (95% CI)
Total sample					
•	Total sample	-1.06 (-3.67, 1.55)	0.08 (-2.71, 2.85)	-1.21 (-3.71, 1.29)	-0.18 (-2.85, 2.48)
	Any symptoms in prior two weeks	-1.22 (-4.33, 1.89)	0.79 (-2.78, 4.33)	-1.27 (-4.25, 1.70)	0.53 (-2.99, 4.00)
	No symptoms in prior two weeks	-1.13 (-6.04, 3.78)		-1.58 (-6.28, 3.12)	
Clinic sample		, · · ,		,	
•	Total sample	-1.26 (-4.07, 1.56)	0.65 (-2.70, 4.02)	-1.47 (-4.24, 1.30)	0.37 (-2.89, 3.66)
	Any symptoms in prior two weeks	-1.29 (-4.79, 2.21)	1.71 (-3.60, 7.13)	-1.40 (489, 2.09)	1.61 (-3.65, 6.94)
	No symptoms in prior two weeks	-1.13 (-5.96, 3.70)		-1.58 (-6.18, 3.01)	
Outreach sample		, , , , , , , , , , , , , , , , , , ,			
	Total sample	0.20 (-6.97, 7.37)		0.46 (-6.08, 7.00)	
	Any symptoms in prior two weeks	-0.90 (-8.16, 6.37)		-0.67 (-6.94, 5.60)	
	No symptoms in prior two weeks	/		,	

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Pneumococcal detection was defined as C<sub>T</sub> values below 35 for both the *lytA* and *piaB* targets. Adjusted analyses include data from participants enrolled in the primary study only. We indicate dashes where models lacked sufficient sample to converge for all parameter estimates.



**Figure S1: Correlation between** *lytA* and *piaB*  $C_T$  values among pneumococcal carriers. Panels illustrate  $C_T$  values for all individuals found to carry pneumococci (based on  $C_T$  for both *lytA* and *piaB*; left) and for individuals with  $C_T$  values below 35 for both *lytA* and *piaB* (right).




Figure S2: Correlation of qPCR C<sub>7</sub> value for SARS-CoV-2 and pneumococcal gene targets in saliva samples.

Panels illustrate  $C_T$  values for the SARS-CoV-2 nucleocapsid (N; top panels) and structural envelope protein (E; bottom panels) genes against  $c_T$  values for the pneumococcal *lytA* (left panels) and *piaB* (right panels) genes. Data are subset to individuals found to be infected with SARS-CoV-2 and to carry pneumococci.